[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 626
1. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • [Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • The average age at diagnosis was 63.4 years.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • Most patients had squamous cell carcinoma (n=30).
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


2. Gagne SE, Jensen R, Polvi A, Da Costa M, Ginzinger D, Efird JT, Holly EA, Darragh T, Palefsky JM: High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia. J Acquir Immune Defic Syndr; 2005 Oct 1;40(2):182-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia.
  • Anal intraepithelial neoplasia (AIN) is the likely precursor to anal cancer.
  • AIN is associated with human papillomavirus (HPV) infection, and HPV-associated genomic instability may play an important role in the progression of squamous intraepithelial neoplasia to cancer.
  • HPV16 DNA integration or rearrangement correlated with CNAs in host cell DNA (P = 0.007).
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Genome, Viral. Papillomaviridae / physiology. Virus Integration

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186736.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NCI NIH HHS / CA / R01CA54053; United States / NCI NIH HHS / CA / U01 CA66529; United States / NCI NIH HHS / CA / U01 CA70019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


3. Driemel O, Kunkel M, Hullmann M, Kleinsasser N, Staudenmaier R, Müller-Richter U, Reichert TE, Kosmehl H: [Performance of conventional oral brush biopsies]. HNO; 2008 Feb;56(2):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study evaluated the performance of oral brush biopsies using standard morphological analysis and haematoxylin and eosin (HE) staining for detecting oral squamous cell carcinomas and their respective precursor lesions PATIENTS AND METHODS: Brush biopsies were obtained in 169 consecutive patients who underwent routine biopsies and histological examination for clinically suspicious oral lesions.
  • RESULTS: Despite a sufficient number of cells, a definite cytological diagnosis could not be established in six cases.
  • Thus, this technique should not be used for diagnostic proof or to exclude malignant cells in a lesion suspicious for cancer.
  • [MeSH-major] Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]
  • [Cites] Mol Cancer. 2006 Mar 23;5:11 [16556320.001]
  • [Cites] Dtsch Zahnarztl Z. 1981 Nov;36(11):701-3 [6946905.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Oct;34(5):461-6 [8909744.001]
  • [Cites] Dtsch Med Wochenschr. 1978 Jan 6;103(1):17-20 [620647.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]
  • [Cites] N Engl J Med. 2001 May 24;344(21):1603-7 [11372013.001]
  • [Cites] Mund Kiefer Gesichtschir. 2007 Jan;11(1):1-9 [17177045.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1991 Jan;51(1):51-3 [2026300.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):405-8 [7536508.001]
  • [Cites] Dtsch Zahnarztl Z. 1981 Nov;36(11):697-700 [6946904.001]
  • [Cites] Ann Intern Med. 1949 Oct;31(4):661-74 [15392502.001]
  • [Cites] Int J Oral Maxillofac Surg. 2000 Dec;29(6):453-7 [11202330.001]
  • [Cites] Science. 1942 Apr 24;95(2469):438-9 [17842594.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] Acta Cytol. 1963 Mar-Apr;7:107-10 [13978631.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]
  • [Cites] Stomatol DDR. 1986 Dec;36(12):712-6 [2438824.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Apr;64(4):628-35 [16546642.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]
  • [Cites] J Dent Res. 1951 Jun;30(3):308-13 [14841304.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 Mar;10(2):89-93 [16485137.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]
  • [Cites] Br J Cancer. 1971 Mar;25(1):21-4 [5581297.001]
  • [Cites] APMIS. 2005 Mar;113(3):208-12 [15799765.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Nov;6(6):410-4 [12447653.001]
  • [Cites] Gen Dent. 2000 Nov-Dec;48(6):656-60 [12004660.001]
  • [Cites] Head Neck. 2002 Mar;24(3):223-7 [11891953.001]
  • [Cites] Oral Oncol. 2002 Feb;38(2):125-30 [11854058.001]
  • [Cites] Int Dent J. 1968 Dec;18(4):708-23 [5252708.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1984 Aug;44(8):485-94 [6566637.001]
  • [Cites] J Indiana Dent Assoc. 2001 Summer;80(2):6-8 [11693004.001]
  • [Cites] Cytopathology. 1994 Feb;5(1):47-53 [8173031.001]
  • [Cites] Dtsch Zahnarztl Z. 1966 Jan 1;21(1):145-8 [5216203.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]
  • (PMID = 18214406.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Varnai AD, Bollmann M, Griefingholt H, Speich N, Schmitt C, Bollmann R, Decker D: HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis; 2006 Mar;21(2):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis.
  • BACKGROUND AND AIMS: Majority of cases of anal squamous cell carcinoma are human papilloma virus (HPV)-induced and result from anal intraepithelial neoplasia (AIN).
  • This study was conducted to examine methods which may enable the routine diagnosis of HPV-induced changes in the anal rim and the consequences of such detection especially in view of a more sensitive diagnosis of AIN.
  • METHODS: The study included biopsy samples from 87 patients who had been diagnosed with the following disease patterns: 47 invasive anal carcinoma, 33 AIN of varying severity and seven condylomatous lesions.
  • RESULTS: In 38 of 47 cases of anal carcinoma, HPV DNA could be detected via PCR (80.9%), the majority of which were HPV 16 (33/38=86.8%).
  • DISCUSSION: In our series, the clinical diagnosis of the invasive anal carcinoma had a high sensitivity of 93.6%, with a specificity of 80%.
  • In this situation, especially with high-risk patients, our findings recommend anal HPV screening in combination with anal cytology and anoscopy.
  • CONCLUSION: Based on our results, we urgently recommend for any histological report on excision of anal lesions to include a statement whether histological markers of HPV infection were detected.
  • [MeSH-major] Alphapapillomavirus / genetics. Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Colorectal Dis. 2007 Oct;22(10):1289 [16703315.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):57-62 [12589647.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1534-8 [9836490.001]
  • [Cites] Cytopathology. 1998 Feb;9(1):15-22 [9523124.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Sao Paulo Med J. 2003 May 5;121(3):128-32 [12920476.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):203-6 [2166709.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2229-42 [12441259.001]
  • [Cites] Br J Cancer. 1997;76(10):1271-8 [9374370.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1167-70 [9250316.001]
  • [Cites] Cancer Lett. 1998 Jan 16;123(1):47-52 [9461017.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):692-9 [12861066.001]
  • [Cites] J Clin Microbiol. 1990 Dec;28(12):2739-43 [2177751.001]
  • [Cites] J Med Microbiol. 2004 Feb;53(Pt 2):125-8 [14729933.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):173-8 [10067816.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Cytopathology. 2005 Feb;16(1):13-21 [15859310.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):270-4 [7617653.001]
  • [Cites] Scand J Infect Dis. 1996;28(6):629-32 [9060069.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):345-51 [3568924.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Dan Med Bull. 2002 Aug;49(3):194-209 [12238281.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):19-26 [14968414.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Dtsch Med Wochenschr. 2003 Sep 19;128(38):1957-62 [14502448.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):958-67 [7842416.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):113-7 [12704691.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • (PMID = 15864603.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


5. Pepek JM, Willett CG, Czito BG: Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw; 2010 Jan;8(1):123-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy advances for treatment of anal cancer.
  • Radiation therapy (RT) is established as the primary treatment of squamous cell carcinoma of the anus.
  • [MeSH-major] Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064294.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


6. Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA: p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging; 2010 Feb;37(2):250-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / pharmacokinetics. Carcinoma, Squamous Cell / metabolism. Chelating Agents / chemistry. Deferoxamine / analogs & derivatives. Isothiocyanates / chemistry. Positron-Emission Tomography / methods. Radioisotopes / pharmacokinetics. Zirconium / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Isotope Labeling / methods. Metabolic Clearance Rate. Mice. Mice, Nude. Organ Specificity. Radioimmunodetection / methods. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2003 Aug;44(8):1271-81 [12902418.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45 [16832633.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10):1663-70 [14530484.001]
  • [Cites] Mol Imaging. 2003 Jul;2(3):131-7 [14649056.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):155-63 [15186595.001]
  • [Cites] Cancer. 1972 Jan;29(1):117-21 [4332311.001]
  • [Cites] J Nucl Med. 1982 Oct;23(10):909-14 [7119886.001]
  • [Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]
  • [Cites] Anal Biochem. 1984 Oct;142(1):68-78 [6440451.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1189-94 [3422590.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):1188-94 [2786509.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4383-90 [8364934.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):878-84 [7850803.001]
  • [Cites] J Nucl Med. 1996 Feb;37(2):352-62 [8667076.001]
  • [Cites] J Nucl Med. 1996 Aug;37(8):1384-8 [8708780.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):112-8 [8998164.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):410-5 [9139877.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1898-906 [16269605.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40 [16609026.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] Phys Med Biol. 2007 Mar 7;52(5):1505-26 [17301468.001]
  • [Cites] J Nucl Med. 2007 Aug;48(8):1313-9 [17631557.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1379-89 [18165614.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Sep15;60(12):1347-70 [18538888.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67 [18491091.001]
  • [Cites] J Nucl Med. 2009 Jan;50(1):2-5 [19091888.001]
  • [Cites] Bioconjug Chem. 2009 May 20;20(5):825-41 [19125647.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Aug;18(4):655-61 [14503961.001]
  • (PMID = 19763566.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 4-isothiocyanatobenzyl-desferrioxamine; 0 / Antibodies, Monoclonal; 0 / Chelating Agents; 0 / Isothiocyanates; 0 / Radioisotopes; 0 / Radiopharmaceuticals; C6V6S92N3C / Zirconium; J06Y7MXW4D / Deferoxamine
  • [Other-IDs] NLM/ PMC2816257
  •  go-up   go-down


7. Goldstone SE, Hundert JS, Huyett JW: Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis Colon Rectum; 2007 May;50(5):565-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males.
  • PURPOSE: The incidence of anal squamous carcinoma in males who have sex with males is rising.
  • We reported that infrared coagulation of high-grade squamous intraepithelial lesions in HIV-positive males who have sex with males yielded a recurrence rate after the first ablation of 65 percent and 58 percent after a second ablation.
  • METHODS: We performed a retrospective review of medical records on HIV-negative males who have sex with males who had infrared coagulation ablation of anal high-grade squamous intraepithelial lesions.
  • Recurrent high-grade squamous intraepithelial lesions were retreated.
  • HIV-positive patients were twice as likely to have lesions persist and 1.7 times more likely to develop a recurrent high-grade squamous intraepithelial lesion.
  • No patient developed squamous-cell carcinoma, anal stenosis, or had a serious complication.
  • CONCLUSIONS: Infrared coagulation is a safe and effective office-based procedure for treating anal high-grade squamous intraepithelial lesions.
  • Although recurrence was high after the first infrared coagulation, repeated treatment led to resolution of high-grade squamous intraepithelial lesions.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. HIV Seronegativity. Homosexuality, Male. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380365.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H, Begg AC: Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol; 2008 May;61(6):1075-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No evidence of a correlation was found between adduct levels in normal tissues and primary tumor biopsies.
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / radiotherapy. Humans. Leukocyte Count. Mouth Mucosa / cytology. Predictive Value of Tests

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Jan;79(1):82-8 [10408697.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):750-6 [16550603.001]
  • [Cites] Anal Biochem. 1999 Nov 1;275(1):30-8 [10542106.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):160-6 [10754494.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2992-9 [12231546.001]
  • [Cites] Clin Pharmacol Ther. 2003 May;73(5):417-26 [12732842.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Eur J Cancer Clin Oncol. 1986 Mar;22(3):257-63 [3709595.001]
  • [Cites] Radiother Oncol. 1986 May;6(1):61-74 [3715061.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Nov;50(5):871-84 [3490450.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):3000-4 [3552211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5024-8 [3110781.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6134-7 [3664513.001]
  • [Cites] Carcinogenesis. 1988 Oct;9(10):1909-11 [2458857.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3556-61 [2340504.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7887-94 [2253228.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2828-32 [2025848.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):612-7 [8499090.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):229-34 [8318875.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5669-75 [8242622.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2843-52 [7514956.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):512-7 [7880732.001]
  • [Cites] Carcinogenesis. 1995 Oct;16(10):2447-53 [7586150.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):23-31 [7497593.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):150-4 [7497585.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1569-75 [8664132.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):452-6 [8945615.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Clin Cancer Res. 1996 Jun;2(6):1063-6 [9816268.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1829-35 [9816137.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1963-71 [16287073.001]
  • (PMID = 17639394.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2270367
  •  go-up   go-down


9. Zuo QP, Li B, Pei Q, Li Z, Liu SK: A highly selective fluorescent probe for detection of biological samples thiol and its application in living cells. J Fluoresc; 2010 Nov;20(6):1307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This fluorescent molecular probe consists of a thiol reaction moiety bound to a coumarin fluorophore.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Fluorescent Dyes / chemistry. Sulfhydryl Compounds / analysis. Tongue Neoplasms / chemistry

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Chem Soc. 2003 Jul 2;125(26):7802-3 [12822989.001]
  • [Cites] Clin Chem. 1990 Dec;36(12):2137-8 [2253363.001]
  • [Cites] Chem Commun (Camb). 2009 Aug 14;(30):4530-2 [19617973.001]
  • [Cites] J Am Chem Soc. 2007 Aug 29;129(34):10322-3 [17672463.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 May 6;44(19):2922-5 [15818626.001]
  • [Cites] Org Lett. 2008 Jan 3;10(1):37-40 [18062694.001]
  • [Cites] Anal Biochem. 2007 Dec 1;371(1):71-81 [17727809.001]
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2001 Oct;57(12):2403-7 [11767834.001]
  • [Cites] J Pharm Biomed Anal. 2008 Dec 15;48(5):1375-80 [18926658.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):230-6 [9227928.001]
  • [Cites] Anal Chim Acta. 2008 Jul 14;620(1-2):120-6 [18558132.001]
  • [Cites] Chem Commun (Camb). 2003 Jan 7;(1):146-7 [12611008.001]
  • [Cites] Bioelectrochemistry. 2004 Jun;63(1-2):19-24 [15110242.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(41):7883-7 [18781571.001]
  • [Cites] Anal Chem. 2007 Nov 15;79(22):8769-73 [17924649.001]
  • [Cites] Anal Chem. 2000 Dec 1;72(23):5755-60 [11128932.001]
  • [Cites] Cancer Lett. 2004 May 28;208(2):143-53 [15142672.001]
  • [Cites] Org Lett. 2009 Nov 5;11(21):4918-21 [19788282.001]
  • [Cites] Chem Commun (Camb). 2004 Aug 7;(15):1762-3 [15278174.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(22):4034-7 [19388016.001]
  • [Cites] Org Lett. 2007 Aug 16;9(17 ):3375-7 [17645349.001]
  • [Cites] Bioorg Med Chem Lett. 2008 Apr 1;18(7):2246-9 [18358719.001]
  • [Cites] Clin Chem. 1998 Aug;44(8 Pt 2):1833-43 [9702993.001]
  • [Cites] J Nutr. 2006 Jun;136(6 Suppl):1682S-1693S [16702340.001]
  • [Cites] N Engl J Med. 2002 Feb 14;346(7):476-83 [11844848.001]
  • [Cites] J Chromatogr. 1985 Feb 27;338(1):209-12 [4019645.001]
  • [Cites] Anal Chem. 2001 Dec 15;73(24):5972-8 [11791568.001]
  • [Cites] Anal Chem. 2002 Mar 15;74(6):1349-54 [11922303.001]
  • [Cites] Eur J Biochem. 2000 Aug;267(16):4904-11 [10931172.001]
  • [Cites] Talanta. 2003 Aug 29;60(6):1229-38 [18969150.001]
  • [Cites] J Fluoresc. 2009 Jul;19(4):593-9 [19050997.001]
  • [Cites] Neurosci Lett. 1990 Mar 2;110(1-2):216-20 [2325885.001]
  • [Cites] Amino Acids. 2009 Jul;37(2):395-400 [18695935.001]
  • [Cites] Chem Commun (Camb). 2005 Jul 7;(25):3189-91 [15968367.001]
  • [Cites] Chemistry. 2009;15(20):5096-103 [19343759.001]
  • [Cites] Anal Chim Acta. 2008 Oct 10;627(2):254-7 [18809081.001]
  • [Cites] J Clin Invest. 1960 Nov;39(11):1633-8 [16695834.001]
  • (PMID = 20473559.001).
  • [ISSN] 1573-4994
  • [Journal-full-title] Journal of fluorescence
  • [ISO-abbreviation] J Fluoresc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Sulfhydryl Compounds
  •  go-up   go-down


10. Patel H, Polanco-Echeverry G, Segditsas S, Volikos E, McCart A, Lai C, Guenther T, Zaitoun A, Sieber O, Ilyas M, Northover J, Silver A: Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. Int J Cancer; 2007 Dec 15;121(12):2668-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
  • Human papilloma virus (HPV) infection is considered as an important aetiological factor for anal squamous cell carcinoma (ASCC) but is not sufficient for tumour progression.
  • This carcinoma is poorly understood at the molecular level.
  • [MeSH-major] Anus Neoplasms / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Mutation. Papillomaviridae / isolation & purification. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17721920.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


11. Houvenaeghel G, Ghouti L, Moutardier V, Buttarelli M, Lelong B, Delpero JR: Rectus abdominis myocutaneous flap in radical oncopelvic surgery: a safe and useful procedure. Eur J Surg Oncol; 2005 Dec;31(10):1185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Between 1989 and 1998, 46 patients underwent pelvi-perineal reconstruction with RAM flaps after radical pelvic surgery for carcinoma of the cervix (n=22), anal carcinoma (n=11), rectal carcinoma (n=7), or other pelvic tumours types (n=6).

  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126359.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Kovar JL, Volcheck WM, Chen J, Simpson MA: Purification method directly influences effectiveness of an epidermal growth factor-coupled targeting agent for noninvasive tumor detection in mice. Anal Biochem; 2007 Feb 1;361(1):47-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Binding of IRDye 800CW EGF to intact A431 human epidermoid carcinoma cells was quantified in a microplate assay.
  • This is the first study to directly correlate targeting agent signal strength in whole cell binding, In-Cell Western, and in vivo near-infrared imaging.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epidermal Growth Factor
  • [MeSH-minor] Animals. Cell Line, Tumor. Chromatography, Gel. Chromatography, High Pressure Liquid. Coloring Agents. Humans. Indicators and Reagents. Mice. Mice, Nude. Mice, SCID. Receptor, Epidermal Growth Factor. Sensitivity and Specificity. Spectrometry, Fluorescence / methods. Transplantation, Heterologous

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):600-14 [12154371.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):849-57 [12213713.001]
  • [Cites] Amino Acids. 2002;23(1-3):301-8 [12373551.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3438-44 [12429632.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S9-14 [12867057.001]
  • [Cites] Curr Opin Chem Biol. 2003 Oct;7(5):626-34 [14580568.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7870-5 [14633715.001]
  • [Cites] Mol Imaging. 2003 Oct;2(4):303-12 [14717329.001]
  • [Cites] Nat Biotechnol. 2004 Feb;22(2):198-203 [14704683.001]
  • [Cites] Mol Cancer Ther. 2004 Apr;3(4):481-8 [15078992.001]
  • [Cites] Mol Imaging. 2004 Jan;3(1):9-23 [15142408.001]
  • [Cites] Science. 1977 Dec 23;198(4323):1264-7 [929199.001]
  • [Cites] EMBO J. 1987 Mar;6(3):605-10 [3034598.001]
  • [Cites] Am J Pathol. 2006 Oct;169(4):1415-26 [17003496.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):327-31 [11283589.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):313-20 [15765087.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):343-51 [15802051.001]
  • [Cites] Anal Biochem. 2005 Mar 1;338(1):136-42 [15707944.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8009-14 [15520209.001]
  • [Cites] Biochemistry. 1993 Nov 16;32(45):12039-45 [8218281.001]
  • [Cites] Curr Opin Oncol. 1993 May;5(3):474-80 [8494908.001]
  • [Cites] Annu Rev Biophys Biophys Chem. 1991;20:1-28 [1867711.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1433-41 [16287239.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):439-47 [16285906.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41205 [16178629.001]
  • [Cites] Drugs Today (Barc). 2005 Feb;41(2):107-27 [15821783.001]
  • (PMID = 17188228.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106584
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Indicators and Reagents; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS16673; NLM/ PMC1866276
  •  go-up   go-down


13. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, Crum NF: Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer; 2005 Oct 1;104(7):1505-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer incidence rates were race specific and were adjusted for age; these were compared with national rates using logistic regression to assess predictors of NADC development.
  • The most frequent NADCs were skin carcinomas (basal cell and squamous cell), Hodgkin disease, and anal carcinoma.
  • The results showed that there were higher rates of melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease among the HIV-infected cohort compared with age-adjusted rates for the general United States population.
  • A low CD4 nadir or CD4 count at diagnosis (< 200 cells/mL) was not predictive of NADCs.
  • CONCLUSIONS: The most frequent NADCs were primary skin malignancies.
  • Melanoma, basal and squamous cell skin carcinomas, anal carcinoma, prostate carcinoma, and Hodgkin disease occurred at higher rates among HIV-infected individuals.
  • [MeSH-minor] Adult. Age Distribution. Aged. Analysis of Variance. Cohort Studies. Comorbidity. Female. HIV Infections / diagnosis. HIV Infections / epidemiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Probability. Prognosis. Retrospective Studies. Risk Factors. Severity of Illness Index. Sex Distribution. Survival Analysis. United States / epidemiology


14. Li M, Gray W, Zhang H, Chung CH, Billheimer D, Yarbrough WG, Liebler DC, Shyr Y, Slebos RJ: Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res; 2010 Aug 6;9(8):4295-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling.
  • Shotgun proteomics provides the most powerful analytical platform for global inventory of complex proteomes using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and allows a global analysis of protein changes.
  • Nevertheless, sampling of complex proteomes by current shotgun proteomics platforms is incomplete, and this contributes to variability in assessment of peptide and protein inventories by spectral counting approaches.
  • Thus, shotgun proteomics data pose challenges in comparing proteomes from different biological states.
  • We developed an analysis strategy using quasi-likelihood Generalized Linear Modeling (GLM), included in a graphical interface software package (QuasiTel) that reads standard output from protein assemblies created by IDPicker, an HTML-based user interface to query shotgun proteomic data sets.
  • This approach was compared to four other statistical analysis strategies: Student t test, Wilcoxon rank test, Fisher's Exact test, and Poisson-based GLM.
  • We analyzed the performance of these tests to identify differences in protein levels based on spectral counts in a shotgun data set in which equimolar amounts of 48 human proteins were spiked at different levels into whole yeast lysates.
  • Both GLM approaches and the Fisher Exact test performed adequately, each with their unique limitations.
  • We subsequently compared the proteomes of normal tonsil epithelium and HNSCC using this approach and identified 86 proteins with differential spectral counts between normal tonsil epithelium and HNSCC.
  • We selected 18 proteins from this comparison for verification of protein levels between the individual normal and tumor tissues using liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS).
  • This analysis confirmed the magnitude and direction of the protein expression differences in all 6 proteins for which reliable data could be obtained.
  • Our analysis demonstrates that shotgun proteomic data sets from different tissue phenotypes are sufficiently rich in quantitative information and that statistically significant differences in proteins spectral counts reflect the underlying biology of the samples.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biometrics. 2001 Jun;57(2):620-4 [11414592.001]
  • [Cites] J Proteome Res. 2010 Feb 5;9(2):761-76 [19921851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Anal Chem. 2002 Jul 1;74(13):3076-83 [12141667.001]
  • [Cites] Dis Markers. 2002;18(2):99-105 [12364816.001]
  • [Cites] Nat Biotechnol. 2003 Mar;21(3):262-7 [12610573.001]
  • [Cites] J Proteome Res. 2003 Nov-Dec;2(6):643-9 [14692458.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i31-9 [15262778.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):985-92 [15258593.001]
  • [Cites] Biometrics. 1991 Jun;47(2):383-401 [1912253.001]
  • [Cites] J Invest Dermatol. 1992 Sep;99(3):299-305 [1512466.001]
  • [Cites] Biochem J. 1994 Sep 1;302 ( Pt 2):363-71 [8092987.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):871-6 [8634660.001]
  • [Cites] J Invest Dermatol. 1997 Feb;108(2):200-4 [9008234.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):151-7 [15922867.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6218-24 [16194081.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):971-83 [16900146.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2909-18 [17081042.001]
  • [Cites] BMC Genomics. 2006;7:278 [17074082.001]
  • [Cites] Cardiovasc Res. 2007 Jan 1;73(1):19-25 [17045254.001]
  • [Cites] J Proteome Res. 2007 Feb;6(2):654-61 [17269722.001]
  • [Cites] J Proteome Res. 2007 Sep;6(9):3549-57 [17676885.001]
  • [Cites] J Proteome Res. 2007 Oct;6(10):3962-75 [17711321.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):845-54 [18198819.001]
  • [Cites] Mol Cell Proteomics. 2008 Dec;7(12):2373-85 [18644780.001]
  • [Cites] J Proteome Res. 2008 Dec;7(12):5286-94 [18939861.001]
  • [Cites] Proteomics. 2009 Apr;9(8):2193-201 [19337991.001]
  • [Cites] Nat Biotechnol. 2009 Jul;27(7):633-41 [19561596.001]
  • [Cites] J Oral Pathol Med. 2009 Jul;38(6):530-4 [19222712.001]
  • [Cites] J Proteome Res. 2009 Aug;8(8):3872-81 [19522537.001]
  • [Cites] Bioinformatics. 2010 Feb 1;26(3):363-9 [20007255.001]
  • [Cites] Mol Cell Proteomics. 2010 Feb;9(2):242-54 [19858499.001]
  • [ErratumIn] J Proteome Res. 2010 Nov 5;9(11):6090
  • (PMID = 20586475.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA126479; United States / NCI NIH HHS / CA / 1U24CA126479
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins
  • [Other-IDs] NLM/ PMC2920032
  •  go-up   go-down


15. Lê LH, Chetty R, Moore MJ: Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol; 2005 Jul;124(1):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor expression in anal canal carcinoma.
  • Most anal canal carcinomas (ACCs) are squamous cell carcinomas (SCCs).
  • Therefore, we obtained archived pathology samples from ACC biopsies and examined the frequency and level of expression of EGFR and other cell surface and cell cycle markers.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / metabolism. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Receptor, Epidermal Growth Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923158.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


16. Jahan I, Fujimoto J, Alam SM, Sato E, Tamaya T: Role of protease activated receptor-2 in lymph node metastasis of uterine cervical cancers. BMC Cancer; 2008;8:301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Receptor, PAR-2 / metabolism. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2003 Jul;23(1):61-6 [12792776.001]
  • [Cites] J Histochem Cytochem. 1998 Feb;46(2):157-64 [9446822.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20927-34 [15010475.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1401-6 [15138580.001]
  • [Cites] Mol Cancer Res. 2004 Jul;2(7):395-402 [15280447.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1013-6 [15492786.001]
  • [Cites] Arch Pathol Lab Med. 1985 Aug;109(8):716-21 [3893381.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1584-93 [2418947.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1267-81 [10725339.001]
  • [Cites] J Neural Transm (Vienna). 2001;108(2):125-40 [11314768.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):245-82 [11356985.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2031-41 [11395381.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):772-9 [11531266.001]
  • [Cites] Life Sci. 2002 Feb 8;70(12):1359-67 [11883712.001]
  • [Cites] FEBS Lett. 2002 Jul 17;523(1-3):85-9 [12123809.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1421-6 [12231560.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):703-13 [12548614.001]
  • [Cites] Gynecol Oncol. 1987 Jun;27(2):150-8 [3570054.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Semin Diagn Pathol. 1990 Aug;7(3):173-89 [2218146.001]
  • [Cites] Cancer Metastasis Rev. 1992 Mar;11(1):31-44 [1511495.001]
  • [Cites] Gynecol Oncol. 1998 May;69(2):157-64 [9600824.001]
  • [Cites] Int J Pancreatol. 1998 Oct;24(2):97-102 [9816542.001]
  • [Cites] Cancer Lett. 1999 May 3;139(1):109-13 [10408902.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):307-14 [16397244.001]
  • [Cites] J Surg Oncol. 2006 Feb 1;93(2):139-44 [16425301.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):268-78 [16816379.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):4592-8 [10671485.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):84-9 [7556175.001]
  • [Cites] Biochem J. 1996 Mar 15;314 ( Pt 3):1009-16 [8615752.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):437-42 [12966163.001]
  • (PMID = 18937843.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, PAR-2
  • [Other-IDs] NLM/ PMC2587477
  •  go-up   go-down


17. Charnley N, Choudhury A, Chesser P, Cooper RA, Sebag-Montefiore D: Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer; 2005 Apr 11;92(7):1221-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.
  • Chemoradiotherapy (CRT) is accepted as the standard initial treatment for squamous cell anal cancer.
  • This paper reports the results of a modified regimen for this group of patients.
  • In all, 16 patients with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol.
  • Patients received a dose of 30 Gy to the gross tumour volume plus 3 cm margin in all directions.
  • Only one patient experienced any grade 3 toxicity (skin).
  • This is a well-tolerated regimen for elderly/poor performance patients with anal cancer, which can achieve high rates of local control and survival.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Fluorouracil / therapeutic use. Frail Elderly

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):65-9 [12118566.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2978-81 [15210736.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Radiother Oncol. 1985 Feb;3(2):145-50 [3920734.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]
  • [Cites] Radiology. 1994 May;191(2):569-72 [8153343.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1352-7 [12778060.001]
  • (PMID = 15798772.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361984
  •  go-up   go-down


18. Cranston RD, Hart SD, Gornbein JA, Hirschowitz SL, Cortina G, Moe AA: The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men. Int J STD AIDS; 2007 Feb;18(2):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in a population of HIV-positive men who have sex with men.
  • Due to the increasing incidence of anal cancer in HIV-positive men who have sex with men, and the potential to detect and treat high-grade anal dysplasia--the putative anal cancer precursor--we have introduced an anal cytology screening service.
  • Patients with abnormal anal cytology have follow-up high-resolution anoscopy (HRA) with biopsy of lesions clinically suspicious for high-grade dysplasia.
  • One hundred and sixty-four (67%) men had abnormal anal cytology, and 93 of them had follow-up HRA and anal biopsy.
  • The positive predictive value for any anal cytological abnormality to predict any degree of anal dysplasia was 95.7+/-2.1%, and for any anal cytological abnormality to predict high-grade anal dysplasia was 55.9+/-5.1%.
  • Abnormal anal cytology was highly predicative of anal dysplasia on biopsy.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms. Carcinoma, Squamous Cell. HIV Infections / complications. Homosexuality, Male
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. AIDS-Related Opportunistic Infections / epidemiology. Adult. Aged. Biopsy. Cytological Techniques. Humans. Male. Middle Aged. Predictive Value of Tests. Prevalence

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331275.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. de Veld DC, Bakker Schut TC, Skurichina M, Witjes MJ, Van der Wal JE, Roodenburg JL, Sterenborg HJ: Autofluorescence and Raman microspectroscopy of tissue sections of oral lesions. Lasers Med Sci; 2005;19(4):203-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cluster analysis was applied to find any relationship between spectral shape and lesion type or cell layer.
  • No clustering with regard to lesion type or cell layer was observed.
  • Raman spectra allowed for reliable classification into cell layers, but differences between lesion types were not significant in this study.
  • [MeSH-minor] Carcinoma, Squamous Cell / pathology. Cluster Analysis. Connective Tissue / pathology. Epithelium / pathology. Freeze Drying. Humans. Keratins / metabolism. Mouth Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc Clin N Am. 2003 Apr;13(2):279-96 [12916660.001]
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • [Cites] J Biomed Opt. 2001 Jan;6(1):41-51 [11178579.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):1047-52 [14601068.001]
  • [Cites] Lasers Surg Med. 1992;12(1):63-78 [1614265.001]
  • [Cites] Photochem Photobiol. 1998 Jul;68(1):123-32 [9679458.001]
  • [Cites] J Invest Dermatol. 2002 Jul;119(1):64-9 [12164926.001]
  • [Cites] Am J Obstet Gynecol. 2002 Mar;186(3):374-82 [11904594.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):396-402 [12612529.001]
  • [Cites] J Biomed Opt. 2004 Sep-Oct;9(5):940-50 [15447015.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1630-5 [11597937.001]
  • [Cites] Photochem Photobiol. 1997 Oct;66(4):418-23 [9337612.001]
  • [Cites] Photochem Photobiol. 1996 May;63(5):662-71 [8628758.001]
  • [Cites] J Am Paraplegia Soc. 1994 Oct;17(4):161-4 [7869057.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] Head Neck. 1998 Sep;20(6):556-62 [9702544.001]
  • [Cites] Anal Chem. 2000 Dec 15;72(24):6010-8 [11140770.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):106-8 [12838309.001]
  • [Cites] Technol Cancer Res Treat. 2003 Aug;2(4):327-32 [12892515.001]
  • [Cites] Biopolymers. 2001;62(4):185-92 [11391568.001]
  • (PMID = 15772873.001).
  • [ISSN] 0268-8921
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


20. Harris AT, Rennie A, Waqar-Uddin H, Wheatley SR, Ghosh SK, Martin-Hirsch DP, Fisher SE, High AS, Kirkham J, Upile T: Raman spectroscopy in head and neck cancer. Head Neck Oncol; 2010 Oct 05;2:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raman spectroscopy in head and neck cancer.
  • In recent years there has been much interest in the use of optical diagnostics in cancer detection.
  • Early diagnosis of cancer affords early intervention and greatest chance of cure.
  • Raman has been used successfully in key health areas such as cardiovascular diseases, and dental care but there is a paucity of literature on Raman spectroscopy in Head and Neck cancer.
  • Following the introduction of health care targets for cancer, and with an ever-aging population the need for rapid cancer detection has never been greater.
  • Raman spectroscopy could confer great patient benefit with early, rapid and accurate diagnosis.
  • It could reduce the need for whole pathological specimen examination, in theatre it could help to determine margin status, and finally peripheral blood diagnosis may be an achievable target.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • [Cites] Eur J Med Res. 2010 Mar 30;15(3):131-4 [20452899.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1756-63 [11037840.001]
  • [Cites] Br J Dermatol. 2002 Mar;146(3):448-57 [11952545.001]
  • [Cites] J Biomed Opt. 2003 Jan;8(1):121-47 [12542388.001]
  • [Cites] Lasers Surg Med. 2003;32(3):210-4 [12605428.001]
  • [Cites] Gastrointest Endosc. 2003 Mar;57(3):396-402 [12612529.001]
  • [Cites] Photochem Photobiol. 2003 Aug;78(2):197-204 [12945589.001]
  • [Cites] Anal Chem. 2003 Dec 1;75(23):6679-86 [14640745.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):443-9 [15009728.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):59-68 [15047215.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1180-92 [15258901.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):860-8 [15513990.001]
  • [Cites] Lasers Surg Med. 2005 Sep;37(3):192-200 [16127671.001]
  • [Cites] Biopolymers. 2006 Feb 15;81(3):179-93 [16231284.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):221-8 [16140566.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3317-22 [16540686.001]
  • [Cites] J Biomed Opt. 2006 Mar-Apr;11(2):021003 [16674178.001]
  • [Cites] Bioinformatics. 2006 Oct 15;22(20):2565-6 [16882648.001]
  • [Cites] Biochem Soc Trans. 2007 Jun;35(Pt 3):544-9 [17511648.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):785-98 [18203445.001]
  • [Cites] Analyst. 2008 Oct;133(10):1416-23 [18810290.001]
  • [Cites] Biopolymers. 2009 Jul;91(7):539-46 [19226625.001]
  • [Cites] Head Neck Oncol. 2009;1:25 [19594907.001]
  • [Cites] Head Neck Oncol. 2009;1:34 [19761601.001]
  • [Cites] Head Neck Oncol. 2009;1:38 [19863815.001]
  • [Cites] Oral Oncol. 2009 Dec;45(12):1006-10 [19828359.001]
  • [Cites] Int J Gynecol Cancer. 2010 Feb;20(2):283-7 [20134271.001]
  • [Cites] Expert Rev Anticancer Ther. 2010 Mar;10(3):321-9 [20214513.001]
  • [Cites] Anal Chem. 2000 Aug 15;72(16):3771-5 [10959962.001]
  • (PMID = 20923567.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2958871
  •  go-up   go-down


21. Wang L, Xue L, Yan H, Li J, Lu Y: Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep; 2010 Apr;37(4):1971-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells.
  • However, little is known the effect of ROCK on cell adhesion and mobility in esophageal squamous cell cancer (ESCC), one of the most diagnosed cancers in China.
  • All these findings indicate that ROCK signaling pathway plays an important role in cell adhesion and mobility, suggesting that it may be used as a potential target for therapy of ESCC.
  • [MeSH-major] Amides / pharmacology. Carcinoma, Squamous Cell / pathology. Cell Movement / drug effects. Esophageal Neoplasms / pathology. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. rho-Associated Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Line, Tumor. Humans

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatol Res. 2008 Aug;38(8):810-7 [18507693.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jul;295(1):C38-49 [18463228.001]
  • [Cites] Exp Cell Res. 2008 Oct 15;314(17):3162-74 [18694745.001]
  • [Cites] Mol Cancer Res. 2008 Sep;6(9):1410-20 [18819929.001]
  • [Cites] World J Gastroenterol. 2008 May 21;14(19):3054-8 [18494058.001]
  • [Cites] J Craniomaxillofac Surg. 2007 Jan;35(1):1-9 [17296306.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549-57 [18055804.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Oct;291(4):C668-77 [16641163.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jun;20(6):1190-200 [10340938.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3317-25 [12882776.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:405-12 [16387705.001]
  • [Cites] J Biol Chem. 2009 May 29;284(22):15147-57 [19293150.001]
  • [Cites] Int J Oncol. 2008 Sep;33(3):585-93 [18695890.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):777-88 [18791066.001]
  • [Cites] World J Gastroenterol. 2008 Oct 7;14(37):5665-73 [18837082.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2006 May;38(5):318-26 [16680372.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1444-58 [19048123.001]
  • [Cites] Jpn J Cancer Res. 2000 Aug;91(8):811-6 [10965022.001]
  • [Cites] J Cell Biol. 2008 Nov 17;183(4):697-710 [19015318.001]
  • [Cites] Cancer Lett. 2009 Nov 1;284(2):122-30 [19303207.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11305-10 [18685096.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):236-48 [17360108.001]
  • [Cites] Gut. 2009 Aug;58(8):1121-7 [19398441.001]
  • [Cites] Biol Pharm Bull. 2008 Sep;31(9):1802-5 [18758081.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1500-9 [16565385.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] J Pineal Res. 2009 Jan;46(1):15-21 [18482340.001]
  • [Cites] Kobe J Med Sci. 2007;53(3):125-34 [17684444.001]
  • [Cites] Mol Cancer Res. 2005 Aug;3(8):425-33 [16123138.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Histopathology. 2008 Apr;52(5):560-8 [18312357.001]
  • [Cites] J Biol Chem. 2006 Oct 6;281(40):29614-24 [16882662.001]
  • [Cites] Lab Invest. 2007 Nov;87(11):1149-58 [17876296.001]
  • [Cites] Cancer Lett. 2005 Jan 31;218(1):69-79 [15639342.001]
  • (PMID = 19649725.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amides; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 138381-45-0 / Y 27632; EC 2.7.11.1 / rho-Associated Kinases
  •  go-up   go-down


22. Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H: High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investig; 2007 Mar;11(1):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Tenascin / analysis

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):986-90 [15094113.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):505-10 [10762653.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] J Oral Pathol Med. 2006 Sep;35(8):520; author reply 520-2 [16918607.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):719-22 [12209613.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252 [14515857.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] Biochem Cell Biol. 1997;75(6):759-69 [9599665.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):680-7 [9495234.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]
  • [Cites] J Oral Pathol Med. 1994 Nov;23(10):446-50 [7532219.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • [Cites] Gen Dent. 2002 Nov-Dec;50(6):500-3 [12572180.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]
  • (PMID = 17111122.001).
  • [ISSN] 1432-6981
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin
  •  go-up   go-down


23. Seth A, Agarwal A: Apoptotic count as a guide for histological grading of carcinoma esophagus: a light microscopic study. J Lab Physicians; 2009 Jan;1(1):11-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic count as a guide for histological grading of carcinoma esophagus: a light microscopic study.
  • AIMS: The study aims to find out if a correlation between apoptotic count and histological grading exists in squamous cell carcinoma of the esophagus, and also to review the literature on such a relationship in the context of some other tumors.
  • SETTINGS AND DESIGN: Cases of squamous cell carcinoma of the esophagus who presented at a tertiary care center over a period of one year were reviewed.
  • MATERIALS AND METHODS: The endoscopic biopsy specimens of 56 patients of squamous cell carcinoma of esophagus were fixed in 10% buffered formalin, processed for routine paraffin sections, sections taken, stained by hematoxylin and eosin and examined under light microscope, using 40× objective and 10× eyepiece.
  • CONCLUSIONS: Grading of squamous cell carcinoma of esophagus, solely on the basis of apoptotic count can be used in the first place or to corroborate conventional histological grading done on the basis of morphology.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2123-8 [10928164.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):88-101 [8990145.001]
  • [Cites] Indian J Pathol Microbiol. 2001 Jul;44(3):257-9 [12024908.001]
  • [Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]
  • [Cites] Mod Pathol. 2007 Oct;20(10):1036-44 [17643097.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Stroke. 1995 Jul;26(7):1252-7; discussion 1257-8 [7541573.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):826-31 [7790118.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jan;121(1):54-8 [9111093.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):901-11 [9265655.001]
  • [Cites] Anal Quant Cytol Histol. 2002 Apr;24(2):73-80 [12026053.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Dec;34(8):900-6 [15907374.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1811-6 [7728743.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):19-20 [8538735.001]
  • [Cites] Histopathology. 1995 Nov;27(5):469-72 [8575739.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2470-5 [8630413.001]
  • [Cites] Indian J Pathol Microbiol. 2000 Jul;43(3):271-5 [11218671.001]
  • (PMID = 21938242.001).
  • [ISSN] 0974-2727
  • [Journal-full-title] Journal of laboratory physicians
  • [ISO-abbreviation] J Lab Physicians
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167958
  • [Keywords] NOTNLM ; Apoptotic count / histological grading / squamous cell carcinoma esophagus
  •  go-up   go-down


24. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Swoboda J, Stücker M, Schmitt M, Pfister H, Wieland U, German Competence Network HIV/AIDS: Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol; 2010 Jun;162(6):1269-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany.
  • BACKGROUND: Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated potential precursor lesion of anal cancer, is frequent among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).
  • There is a paucity of data published on the progression of high-grade AIN to invasive cancer as well as on clinical and virological characteristics comparing anal margin and anal canal carcinoma.
  • OBJECTIVES: To search for anal carcinoma and AIN in a large series of HIV-positive MSM, to assess treatment response of anal carcinoma, and to analyse lesional HPV spectrum of anal cancers.
  • METHODS: Detection of anal carcinoma and AIN was performed using cytology, high-resolution anoscopy, and histology in case of abnormal findings.
  • Additionally, HPV analyses for 36 high- and low-risk α-HPV types were performed in patients with anal carcinoma.
  • Of these, 116 (26·0%) patients had normal findings, 163 (36·5%) had low-grade AIN, 156 (35·0%) had high-grade AIN, and 11 (2·5%) had anal carcinoma as evidenced by the highest grade of cytology/histology.
  • Five patients with anal cancer, who had refused treatment of their precancerous lesions, had progressed from high-grade AIN to invasive cancer within a median time of 8·6 months.
  • All anal cancers carried high-risk α-HPV types.
  • All five squamous cell carcinomas (SCCs) of the anal canal were HPV16 positive.
  • In contrast, only one of the four anal margin SCCs were HPV16 positive (HPV31, HPV33 and HPV33 + HPV68 were found in the other three anal margin SCCs).
  • In contrast to the cancer biopsies, a broad spectrum of surface high- and low-risk HPV types was found in anal swabs of the patients.
  • Surgical excision resulted in long-term disease control of all anal margin carcinomas, whereas combined chemoradiotherapy in carcinomas of the anal canal was associated with high recurrence rates, high toxicity, and high mortality.
  • CONCLUSIONS: Anal carcinoma and AIN are frequent in HIV-positive men, even in patients participating in anal cancer prevention programmes.
  • High-grade dysplasia in these patients can progress to invasive cancer within a short period of time.
  • Anal margin carcinoma and anal canal carcinoma differ substantially in their lesional HPV spectrum, prognosis and treatment response.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. HIV Seropositivity / complications. Papillomaviridae / isolation & purification

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 British Association of Dermatologists.
  • (PMID = 20184584.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00365729
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


25. García Sar D, Montes-Bayón M, Blanco González E, Sierra LM, Aguado L, Comendador MA, Koellensperger G, Hann S, Sanz-Medel A: Quantitative profiling of in vivo generated cisplatin-DNA adducts using different isotope dilution strategies. Anal Chem; 2009 Dec 1;81(23):9553-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this regard, two novel sensitive and selective strategies are proposed here to quantify cisplatin-DNA adducts generated in Drosophila melanogaster larvae and in head and neck squamous cell carcinoma cultures.
  • Two different strategies, based on isotope dilution analysis (IDA), have been attempted and evaluated for quantification: species-unspecific (the postcolumn addition of a 194Pt-enriched solution) and the species-specific (by means of a synthesized isotopically enriched cisplatin (194Pt) adduct).
  • Species-specific spiking before enzymatic digestion provided accurate and precise analytical results to clearly differentiate between Drosophila samples and carcinoma cell cultures exposed to different cisplatin concentrations.
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Drosophila melanogaster / metabolism. Humans. Indicator Dilution Techniques. Isotopes. Mass Spectrometry. Oligodeoxyribonucleotides / genetics. Oligodeoxyribonucleotides / metabolism

  • FlyBase. FlyBase .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886652.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / Isotopes; 0 / Oligodeoxyribonucleotides; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Hwang HJ, Bestani C, Jiménez R, Masciángioli G, Gutiérrez A, Cartelli C, Rafailovici L, Barugel M, Rodríguez G, Méndez G: [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital]. Acta Gastroenterol Latinoam; 2005;35(2):94-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital].
  • [Transliterated title] El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital.
  • Anal cancers compromise only 1.5% of all digestive tumors.
  • OBJECTIVE: To collect and analyze clinical data from the medical records of all consecutive patients with squamous cell carcinoma of the anal canal (SCCAC) treated by the Oncology Section in 20 years.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127985.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


27. Chou YP, Saito Y, Matsuda T, Nakajima T, Mashimo Y, Moriya Y, Shimoda T: Novel diagnostic methods for early-stage squamous cell carcinoma of the anal canal successfully resected by endoscopic submucosal dissection. Endoscopy; 2009;41 Suppl 2:E283-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel diagnostic methods for early-stage squamous cell carcinoma of the anal canal successfully resected by endoscopic submucosal dissection.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Colonoscopy / methods. Dissection / methods. Intestinal Mucosa / surgery


28. Baudis M: Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer; 2007;7:226
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Related average imbalance patterns were found for clinically distinct entities, e.g. hepatocellular carcinomas (ca.) and ductal breast ca., as well as for histologically related entities (squamous cell ca. of different sites).
  • [MeSH-major] Carcinoma / genetics. Chromosome Aberrations. Chromosome Mapping

  • COS Scholar Universe. author profiles.
  • SciCrunch. BioSharing: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Genet. 1988 Nov;80(3):235-46 [3192213.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1410-8 [10604741.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):383-99 [10639584.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):871-8 [10702404.001]
  • [Cites] J Pathol. 2000 Nov;192(3):301-6 [11054712.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1228-9 [11751233.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):29-37 [11790857.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):63-90 [12072205.001]
  • [Cites] Anal Cell Pathol. 2002;24(2-3):77-87 [12446957.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):494-8 [12712440.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1808-14 [12738738.001]
  • [Cites] Pathologica. 2003 Apr;95(2):71-82 [12768875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1039-44 [14730057.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] BMC Cancer. 2004 Feb 6;4:5 [15018632.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):143-9 [15140403.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Cytogenet Genome Res. 2004;106(1):43-8 [15218240.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):1-9 [15325087.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):682-7 [15483344.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Clin Genet. 1972;3(3):169-79 [4115505.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Hum Genet. 1993 Feb;90(6):584-9 [8383093.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Hum Mol Genet. 1993 Nov;2(11):1907-14 [8281155.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4813-7 [8062283.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Jul 15;82(2):140-5 [7664243.001]
  • [Cites] Blood. 1996 Jan 1;87(1):25-9 [8547649.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):368-75 [8630489.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4 [8981013.001]
  • [Cites] Cytogenet Cell Genet. 1996;75(1):17-21 [8995481.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):406-10 [9090389.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Sep;56(9):999-1008 [9291941.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):372-6 [9408753.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Feb;21(2):172-5 [9491330.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):625-37 [9683604.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):307-16 [9824203.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1283-91 [16979954.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7324-32 [16751803.001]
  • [Cites] J Pathol. 2007 Jan;211(1):18-25 [17072825.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):293-301 [17011066.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):934-44 [16862168.001]
  • [Cites] Bioinformatics. 2007 Feb 15;23(4):450-7 [17150994.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):1-14 [17382262.001]
  • [Cites] Prostate. 2007 May 15;67(7):692-700 [17342750.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2734-8 [17354231.001]
  • [Cites] Pathologe. 2007 Nov;28(6):464-73 [17882420.001]
  • [Cites] Ugeskr Laeger. 2008 Jan 28;170(5):328-30 [18252159.001]
  • [Cites] Hum Genet. 1988 Nov;80(3):224-34 [3192212.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Am J Hum Genet. 1960 Sep;12:250-76 [14430808.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1061-4 [15650359.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):822-7 [15705879.001]
  • [Cites] Acta Pharmacol Sin. 2005 Jun;26(6):659-65 [15916730.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):593-606 [16077907.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):11-9 [16130125.001]
  • [Cites] Biotechniques. 2006 Mar;40(3):269-70, 272 [16568815.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jun;167(2):103-8 [16737908.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):721-30 [16688744.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3961-70 [16818693.001]
  • [Cites] Cell Oncol. 2006;28(3):71-84 [16823176.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4399-412 [16547504.001]
  • [Cites] Bioinformatics. 2006 Aug 15;22(16):1971-8 [16705014.001]
  • [Cites] Cytogenet Genome Res. 2006;115(1):16-22 [16974079.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2308-15 [16728973.001]
  • (PMID = 18088415.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2225423
  •  go-up   go-down


29. Dietz A, Boehm A, Horn IS, Kruber P, Bechmann I, Golusinski W, Niederwieser D, Dollner R, Remmerbach TW, Wittekind C, Dietzsch S, Hildebrandt G, Wichmann G: Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol; 2010 Apr;267(4):483-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article gives an overview on different current strategies of assay-based response evaluation in head and neck squamous cell carcinomas (HNSCC) and critically summarizes their role and needs for future clinical evaluation.
  • Moreover, the outcome is difficult to predict due to heterogeneity of a tumor's response, impaired late functional outcome, and increased late toxicity if simultaneously applied to radiation.
  • Unfortunately, predictive information on response characteristics of a given tumor before starting the therapy is not available in daily routine, although heterogeneity in response of a given tumor entity to treatments has been known for decades.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Combined Modality Therapy / methods. Decision Making. Head and Neck Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Arch Otorhinolaryngol. 2010 Apr;267(4):481-2 [20052588.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3483-8 [19536900.001]
  • [Cites] Cancer Biother Radiopharm. 1998 Apr;13(2):81-7 [10850344.001]
  • [Cites] BMC Cancer. 2006 Mar 06;6:52 [16515711.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):760-7 [18728667.001]
  • [Cites] Cancer Genomics Proteomics. 2007 May-Jun;4(3):175-86 [17878521.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1731-8 [17236202.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S3-12 [18535834.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 4;82(7):582-8 [2313735.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4837-43 [7585517.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 1):5436-41 [4053017.001]
  • [Cites] Mol Vis. 2008 Sep 15;14:1705-12 [18806879.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):233-6 [11252900.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 17;82(2):117-24 [2152944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303 [19306746.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1651-5 [16619587.001]
  • [Cites] Radiother Oncol. 2003 Aug;68(2):163-70 [12972311.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):749-56 [17112769.001]
  • [Cites] Recent Results Cancer Res. 1984;94:197-201 [6494580.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2309-12 [6202397.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2009 Aug;266(8):1291-300 [18972123.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):949-55 [18507041.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 May;134(5):536-8 [18490577.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):325-31 [15015616.001]
  • [Cites] Head Neck. 2008 Dec;30(12):1636-42 [18642286.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):4-14 [19446902.001]
  • [Cites] Oncology. 1992;49(5):343-6 [1528569.001]
  • [Cites] Int J Cancer. 1991 May 30;48(3):423-7 [2040537.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):527-30 [7425237.001]
  • [Cites] Anticancer Res. 1991 May-Jun;11(3):1301-4 [1909515.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3645-6; author reply 3646-8 [15908688.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 17;82(2):96-101 [2403594.001]
  • [Cites] Head Neck. 2002 May;24(5):437-42 [12001073.001]
  • [Cites] Br J Cancer. 1992 Jan;65(1):27-32 [1310250.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1926-31 [6339044.001]
  • [Cites] Mol Pharmacol. 2000 Dec;58(6):1563-9 [11093797.001]
  • [Cites] Cancer Res. 1987 Mar 1;47(5):1297-301 [3469013.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:173-85 [8806100.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3631-8 [15289488.001]
  • [Cites] J Cell Biochem. 2009 May 1;107(1):179-88 [19277990.001]
  • [Cites] Gynecol Oncol. 1995 Jun;57(3):294-8 [7774832.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Apr 15;164(2):134-42 [10764626.001]
  • [Cites] Strahlenther Onkol. 2009 Jun;185(6):371-8 [19506820.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):498-506 [19318632.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 May;65(6):1153-63 [19771432.001]
  • [Cites] Pancreas. 2004 Jan;28(1):38-44 [14707728.001]
  • [Cites] Eur J Cancer. 1980 May;16(5):647-54 [7389791.001]
  • [Cites] Acta Otolaryngol. 1987 May-Jun;103(5-6):529-36 [2441566.001]
  • [Cites] J Clin Lab Anal. 1991;5(2):133-43 [2023059.001]
  • [Cites] Anticancer Drugs. 1998 Jan;9(1):51-7 [9491792.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Radiother Oncol. 1995 Nov;37(2):87-99 [8747932.001]
  • [Cites] Endocr Relat Cancer. 2002 Sep;9(3):171-82 [12237245.001]
  • [Cites] Arch Otolaryngol. 1983 Nov;109(11):709-14 [6314953.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6730-6 [11118059.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):57-66 [15890237.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11 Suppl A:131-7 [6733715.001]
  • [Cites] Oral Oncol. 1998 Jan;34(1):30-8 [9659517.001]
  • [Cites] Radiother Oncol. 2008 Oct;89(1):33-7 [18621428.001]
  • [Cites] Oral Oncol. 2008 Dec;44(12):1100-9 [18487078.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3582-9 [18559875.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):943-7 [15313864.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):827-8 [11022932.001]
  • [Cites] Science. 1977 Jul 29;197(4302):461-3 [560061.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Aug 31;187(1):164-70 [1381586.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):194-201 [16445633.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 15;30(12):1418-25 [11390187.001]
  • [Cites] Onkologie. 2009 May;32(5):264-72 [19420973.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Curr Opin Obstet Gynecol. 2009 Feb;21(1):39-43 [19125002.001]
  • [Cites] Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6 [17504374.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2846-53 [18539963.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Jan;117(1):83-6 [1986767.001]
  • [Cites] Head Neck. 1990 Sep-Oct;12(5):406-10 [2211101.001]
  • [Cites] Onkologie. 2004 Jun;27(3):310-5 [15249723.001]
  • [Cites] Eur J Cancer. 1990;26(7):834-8 [2145907.001]
  • (PMID = 20052589.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


30. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M: Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med; 2005 Mar;2(3):e70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.
  • BACKGROUND: The integrin alphavbeta3 plays an important role in angiogenesis and tumor cell metastasis, and is currently being evaluated as a target for new therapeutic approaches.
  • Moreover, using the A431 human squamous cell carcinoma model we demonstrate that this approach is sensitive enough to visualize alphavbeta3 expression resulting exclusively from the tumor vasculature.
  • [MeSH-minor] Animals. Blotting, Western. Carcinoma, Squamous Cell / radionuclide imaging. Humans. Immunohistochemistry. Melanoma / radionuclide imaging. Mice. Neoplasms / blood supply. Neoplasms / pathology. Neovascularization, Pathologic. Positron-Emission Tomography. Sensitivity and Specificity. Skin Neoplasms / radionuclide imaging. Transplantation, Heterologous

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2625-34 [9829725.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):184-9 [15632051.001]
  • [Cites] J Nucl Med. 1999 Nov;40(11):1771-7 [10565769.001]
  • [Cites] Adv Cancer Res. 2000;79:1-38 [10818676.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3056-61 [10955784.001]
  • [Cites] Magn Reson Med. 2000 Sep;44(3):433-9 [10975896.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):326-36 [11216533.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Eur J Nucl Med. 2001 Feb;28(2):136-43 [11303882.001]
  • [Cites] Semin Oncol. 2001 Oct;28(5 Suppl 16):94-104 [11706401.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Jan;29(1):28-38 [11807604.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):690-7 [11920637.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2404-7 [12089446.001]
  • [Cites] Cell. 2002 Sep 6;110(5):599-11 [12230977.001]
  • [Cites] Bioconjug Chem. 2002 Sep-Oct;13(5):1021-30 [12236784.001]
  • [Cites] Calcif Tissue Int. 2002 Oct;71(4):293-9 [12154391.001]
  • [Cites] Expert Opin Biol Ther. 2002 Dec;2(8):953-66 [12517273.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):83-90 [12635171.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):641-6 [12537667.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):203-13 [12741679.001]
  • [Cites] Chemistry. 2003 Jun 16;9(12):2717-25 [12772286.001]
  • [Cites] Q J Nucl Med. 2003 Sep;47(3):189-99 [12897710.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Jun;4(6):741-5 [12901235.001]
  • [Cites] Angiogenesis. 2002;5(4):237-56 [12906317.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5838-43 [14522907.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):228-30 [14693249.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):61-9 [14733584.001]
  • [Cites] Nucl Med Biol. 2004 Jan;31(1):11-9 [14741566.001]
  • [Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]
  • [Cites] Curr Pharm Des. 2004;10(13):1439-55 [15134568.001]
  • [Cites] J Nucl Med. 2004 May;45(5):892-902 [15136641.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10):1776-83 [15471848.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Biol Chem. 1987 Dec 25;262(36):17703-11 [2447074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819-23 [1712106.001]
  • [Cites] FEBS Lett. 1991 Oct 7;291(1):50-4 [1718779.001]
  • [Cites] Eur J Immunol. 2004 Jun;34(6):1608-16 [15162430.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):231-44 [15186604.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1081-9 [15118844.001]
  • [Cites] Mol Imaging. 2004 Apr;3(2):96-104 [15296674.001]
  • [Cites] Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9 [15380745.001]
  • [Cites] J Clin Invest. 1992 Jun;89(6):2018-22 [1376331.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1188-94 [7515558.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1157-64 [7528107.001]
  • [Cites] J Clin Invest. 1995 Oct;96(4):1815-22 [7560073.001]
  • [Cites] Eur J Nucl Med. 1995 Dec;22(12):1420-32 [8586089.001]
  • [Cites] Science. 1998 Jan 16;279(5349):377-80 [9430587.001]
  • [Cites] Nat Med. 1998 May;4(5):623-6 [9585240.001]
  • [Cites] J Med Chem. 1999 Aug 12;42(16):3033-40 [10447947.001]
  • (PMID = 15783258.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / fluorogalacto-RGD; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ PMC1069665
  •  go-up   go-down


31. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M: The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol; 2008 Jun;87(3):383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer.
  • BACKGROUND AND PURPOSE: To investigate acute and late radiotherapy-related adverse events following intensity-modulated radiotherapy (IMRT) and high dose rate (HDR) brachytherapy of anal cancer.
  • MATERIALS AND METHODS: Fifty-nine consecutive patients treated by chemoradiotherapy for anal squamous cell cancer were evaluated for acute and late radiotherapy-related adverse events.
  • RESULTS: A significant reduction in skin and mucosal eruptions in the female genital area (P=0.04) and in radiotherapy-associated > grade 2 diarrhoea (P=0.004) was observed in patients treated by IMRT.
  • A correlation between the equivalent dose in 2Gy fractions (EQD2) at the wall of anal canal opposite to the tumour and radiation proctitis was observed.
  • CONCLUSIONS: IMRT significantly reduces acute radiotherapy-associated adverse events in patients treated by chemoradiotherapy for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiation Injuries. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501454.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


32. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ: Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg; 2009 Jul;13(7):1292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
  • PURPOSE: The staging of anal cancer is extremely important for therapy and prognosis.
  • METHODS: Forty-five anal cancer patients underwent endoscopic ultrasound and magnetic resonance imaging.
  • Cancer patients were correctly identified with 100% sensitivity (45/45) by endoscopic ultrasound and with 88.9% (40/45) sensitivity by magnetic resonance imaging.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Anus Neoplasms / pathology. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / diagnostic imaging. Carcinoma, Squamous Cell / pathology. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / diagnostic imaging. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Jun 14;14 (22):3504-10 [18567078.001]
  • [Cites] Surg Endosc. 2008 Nov;22(11):2412-5 [18622554.001]
  • [Cites] Int J Colorectal Dis. 2000 Nov;15(5-6):282-90 [11151431.001]
  • [Cites] Endoscopy. 1995 Sep;27(7):469-79 [8565885.001]
  • [Cites] Surg Endosc. 2000 Nov;14 (11):1005-9 [11116406.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):895-900 [17352019.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Dis Colon Rectum. 1986 Apr;29(4):234-42 [3512199.001]
  • [Cites] Int J Colorectal Dis. 1991 Aug;6(3):152-7 [1744487.001]
  • [Cites] Clin Radiol. 2005 Oct;60(10):1111-9 [16179172.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):122-4 [1402307.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10 ):1261-8 [17294198.001]
  • [Cites] Int J Colorectal Dis. 1991 Feb;6(1):2-4 [2033348.001]
  • [Cites] Dis Colon Rectum. 1978 Mar;21(2):89-91 [648293.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):144-8 [16357394.001]
  • [Cites] Radiology. 2004 Sep;232(3):773-83 [15273331.001]
  • [Cites] Eur J Radiol. 2007 Mar;61(3):480-9 [17188828.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2491-9 [12815134.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1347-52 [17643251.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):191-9 [16799791.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]
  • [Cites] Dis Colon Rectum. 1974 Mar-Apr;17(2):181-7 [4819268.001]
  • [Cites] Radiol Med. 2003 Oct;106(4):329-37 [14612825.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]
  • [Cites] Radiology. 2007 Jan;242(1):137-43 [17090719.001]
  • [Cites] J Ultrasound Med. 2006 Jan;25(1):57-73 [16371556.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Radiology. 1990 May;175(2):494-8 [2326475.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19365694.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Alvarez J, de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Allaire G, Hadjeres R, Franco EL, Coutlée F, HIPVIRG Study Group: Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men. AIDS; 2010 Sep 24;24(15):2355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men.
  • OBJECTIVES: To assess levels of episomal and integrated human papillomavirus type 16 (HPV-16) loads in HIV-seropositive men who have sex with men (MSM) in anal infection and to study the association between episomal and integrated HPV-16 loads and anal intraepithelial neoplasia (AIN).
  • Overall, 135 (54.7%) men provided 665 HPV-16-positive anal samples.
  • RESULTS: The HPV-16 DNA forms in anal samples were characterized as episomal only in 627 samples (94.3%), mixed in 22 samples (3.3%) and integrated only in nine samples (1.4%).
  • HPV-16 episomal load [odds ratio (OR) = 1.5, 95% confidence interval (CI) 1.1-2.1], number of HPV types (OR = 1.4, 95% CI 1.1-1.8) and current smoking (OR = 4.8, 95% CI 1.3-18.6) were associated with high-grade AIN (AIN-2,3) after adjusting for age and CD4 cell counts.
  • [MeSH-major] Anus Neoplasms / immunology. Carcinoma, Squamous Cell / immunology. HIV Seropositivity / immunology. Human papillomavirus 16 / immunology. Papillomavirus Infections / immunology. Plasmids / immunology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706109.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Investigator] Allaire G; Baril JG; Boissonnault M; Charest L; Charron MA; Coté S; Coté P; Coutlée F; de Pokomandy A; Dion H; Dufresne S; Falutz J; Fortin C; Franco EL; Ghattas G; Gilmore N; Gorska I; Hadjeres R; Junod P; Klein M; Lalonde R; Laplante F; Leblanc R; Legault D; Lessard B; Longpré D; McLeod J; Maziade JP; Murphy D; Nguyen VK; O'Brien R; Phaneuf D; Rouleau D; Routy JP; Szabo J; Tessier D; Thomas R; Toma E; Tremblay C; Trépanier JM; Trottier B; Tsoukas C; Turner H; Vezina S
  •  go-up   go-down


34. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest; 2008 Jul;118(7):2609-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
  • We investigated mechanisms of acquired resistance to the EGFR TKI gefitinib by generating gefitinib-resistant (GR) A431 squamous cancer cells.
  • Inhibition of IGFIR signaling disrupted the association of IRS-1 with PI3K and restored the ability of gefitinib to downregulate PI3K/Akt signaling and to inhibit GR cell growth.
  • Addition of recombinant IGFBP-3 restored the ability of gefitinib to downregulate PI3K/Akt signaling and to inhibit cell growth.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2493-501 [15710947.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70 [15897464.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4182-90 [15930355.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7275-83 [15282325.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] J Clin Invest. 1985 Oct;76(4):1643-8 [4056043.001]
  • [Cites] Anal Biochem. 1986 Apr;154(1):138-43 [2422981.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 2;84(17):1336-41 [1379645.001]
  • [Cites] Nat Med. 1999 Jul;5(7):810-6 [10395327.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7711-23 [15520175.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):316-28 [15386423.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1515-27 [15979304.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):287-97 [16226704.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Cell. 2006 May 19;125(4):733-47 [16647110.001]
  • [Cites] Nat Rev Genet. 2006 Aug;7(8):606-19 [16847462.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5764-9 [17020982.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6494-501 [17085664.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40183-92 [17082181.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5779-88 [17575145.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40 [17671156.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7807-14 [17699786.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • [Cites] Cancer Biol Ther. 2007 Apr;6(4):534-40 [17457048.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):558-66 [17918155.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7 [18093943.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2137-47 [17952116.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93 [15731348.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):1-9 [10699960.001]
  • [Cites] Blood. 2002 Oct 15;100(8):3041-4 [12351420.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2812-22 [12743604.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [CommentIn] J Clin Invest. 2008 Jul;118(7):2389-92 [18568082.001]
  • (PMID = 18568074.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA080195; United States / NCI NIH HHS / CA / P50 CA98131; United States / NCI NIH HHS / CA / P30 CA68485; United States / NCI NIH HHS / CA / R01 CA80195; United States / NCI NIH HHS / CA / P50 CA098131; United States / NCI NIH HHS / CA / K08 CA120060; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / R00 CA125892; United States / NCI NIH HHS / CA / K08 CA120060-01; United States / NCI NIH HHS / CA / P50 CA127003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Insulin-Like Growth Factor Binding Protein 4; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / Irs1 protein, mouse; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ PMC2430495
  •  go-up   go-down


35. Das P, Cantor SB, Parker CL, Zampieri JB, Baschnagel A, Eng C, Delclos ME, Krishnan S, Janjan NA, Crane CH: Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer; 2010 Feb 15;116(4):822-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term quality of life after radiotherapy for the treatment of anal cancer.
  • BACKGROUND: Radiotherapy is the current standard of care for patients with localized squamous cell cancer of the anal canal.
  • METHODS: Questionnaires were mailed to 80 patients treated with definitive radiotherapy, with or without concurrent chemotherapy, for anal cancer, with a minimum 2-year interval after the completion of radiotherapy.
  • The questionnaire included the Functional Assessment of Cancer Therapy-Colorectal (FACT-C), the Medical Outcomes Study (MOS) Sexual Problems Scale, and questions regarding demographic characteristics and comorbidities.
  • The median total FACT-C score was 108 (range, 47-128), of a maximum (best possible) score of 136.
  • The median score on the MOS Sexual Problems Scale was 67 (range, 0-100), of a maximum (worst possible) score of 100.
  • CONCLUSIONS: Patients treated with radiotherapy for anal cancer reported acceptable overall QoL scores, but poor sexual function scores.
  • [MeSH-major] Anus Neoplasms / psychology. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / radiotherapy. Quality of Life

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20041481.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


36. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


37. Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, Sidransky D: ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle; 2008 Sep 15;7(18):2846-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):305-11 [17224650.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):274-85 [17264681.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):240-5 [17297296.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):246-54 [17297308.001]
  • [Cites] Cell Cycle. 2007 Apr 15;6(8):931-42 [17457059.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1370-80 [17446929.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1062-71 [17426453.001]
  • [Cites] Cell Cycle. 2006 Nov 1;5(21):2489-94 [17106255.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]
  • [Cites] Cell Cycle. 2007 Aug 1;6(15):1831-6 [17671427.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3224-33 [10757806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7 [10805802.001]
  • [Cites] Oncogene. 2000 Jun 22;19(27):3126-30 [10871867.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22719-27 [10801797.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4016-20 [10945600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1817-22 [11172034.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):375-8 [11283598.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1803-15 [11313928.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2764-72 [11358490.001]
  • [Cites] Mol Pharmacol. 2001 Sep;60(3):405-15 [11502869.001]
  • [Cites] Apoptosis. 2007 Oct;12(10):1847-55 [17636382.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2339-40 [17914283.001]
  • [Cites] Cell Cycle. 2007 Dec 15;6(24):3114-31 [18075315.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell Cycle. 2008 May 1;7(9):1231-7 [18418053.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1353-9 [18418074.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):80-9 [14657672.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51408-14 [14555649.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1829-37 [14647429.001]
  • [Cites] Annu Rev Biochem. 2004;73:39-85 [15189136.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] Methods Enzymol. 1991;200:3-37 [1835513.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21396-403 [7545671.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):518-26 [9030780.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):527-36 [9030781.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1674-7 [9733514.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2781-6 [10383130.001]
  • [Cites] J Virol. 2004 Dec;78(24):13501-11 [15564461.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9152-9 [15604286.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1285-95 [15467455.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):37538-43 [10608806.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7803-10 [10713094.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31819-24 [11431470.001]
  • [Cites] Curr Opin Chem Biol. 2001 Oct;5(5):591-602 [11578935.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41717-24 [11546792.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):301-5 [11875433.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]
  • [Cites] Exp Cell Res. 2002 Jun 10;276(2):194-200 [12027449.001]
  • [Cites] Cancer Cell. 2002 May;1(4):369-79 [12086851.001]
  • [Cites] Neoplasia. 2002 Sep-Oct;4(5):400-8 [12192598.001]
  • [Cites] Cell Cycle. 2002 May-Jun;1(3):162-8 [12429926.001]
  • [Cites] Anal Chem. 2002 Nov 1;74(21):5593-9 [12433093.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2264-76 [12640112.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12207-13 [12519769.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2351-7 [12750249.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):936-9 [12782800.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3635-44 [12789272.001]
  • [Cites] Prog Cell Cycle Res. 2003;5:235-48 [14593718.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1358-62 [15492512.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):758-66 [15705872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61 [15788536.001]
  • [Cites] Nat Cell Biol. 2005 May;7(5):493-500 [15834407.001]
  • [Cites] Cell Cycle. 2005 May;4(5):710-6 [15846104.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25485-90 [15899889.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2458-71 [15944736.001]
  • [Cites] Mol Cancer. 2005;4(1):25 [16033649.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6970-5 [16007154.001]
  • [Cites] Int J Mol Med. 2005 Dec;16(6):1065-70 [16273287.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1313-5 [16123597.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1440-7 [16177572.001]
  • [Cites] Neuron. 2005 Dec 8;48(5):743-56 [16337913.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):37-45 [16327781.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):1-2 [16413463.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):45-56 [16413471.001]
  • [Cites] Methods Enzymol. 2005;405:82-115 [16413312.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):38-44 [16359856.001]
  • [Cites] Cell Cycle. 2006 Jun;5(12):1342-7 [16760655.001]
  • [Cites] Laryngoscope. 2006 Aug;116(8):1390-6 [16885742.001]
  • [Cites] Laryngoscope. 2006 Aug;116(8):1409-16 [16885745.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7870-9 [16912160.001]
  • [Cites] Development. 2006 Dec;133(23):4783-92 [17079275.001]
  • (PMID = 18769144.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / DE013561-08; United States / NIDCR NIH HHS / DE / R01 DE013561; United States / NIDCR NIH HHS / DE / R01 DE013561-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 1114-81-4 / Phosphothreonine; 17885-08-4 / Phosphoserine; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS280819; NLM/ PMC3069617
  •  go-up   go-down


38. Kagawa R, Yamaguchi T, Furuta R: Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma. Surg Today; 2006;36(10):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological features of human papilloma virus 16 and its association with the development and progression of anal squamous cell carcinoma.
  • PURPOSE: To investigate the development of anal squamous cell carcinoma (SCC) and the expression patterns of human papillomavirus (HPV).
  • The expression patterns of HPV in the cancer cell nuclei was investigated by in situ hybridization (ISH) using HPV probes.
  • RESULTS: Amplification of DMD genes was confirmed in 8 of 20 patients with anal SCC, suggesting that tumor DNA was preserved in these patients.
  • In two patients with carcinoma in situ (CIS), the cancer cells showed only a diffuse pattern (DP), and in two patients with invasive cancer, the cancer cell showed only an oligo-dot pattern (OP).
  • In one patient with lesions ranging from CIS to invasive cancer, the histologic features varied in each area, from DP to OP.
  • CONCLUSIONS: These findings show that HPV16 infection is closely involved in the development of anal SCC and suggest that the change in the genome occurs at the stage of microinvasive cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. DNA, Viral / genetics. Human papillomavirus 16 / genetics. Papillomavirus Infections / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Biosci. 2002 Mar 01;7:e77-84 [11861218.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] Am J Surg Pathol. 1986 Jan;10(1):1-8 [3006523.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):8-11 [2163992.001]
  • [Cites] Nucleic Acids Res. 1988 Dec 9;16(23):11141-56 [3205741.001]
  • [Cites] Jpn J Cancer Res. 1991 May;82(5):524-31 [1648051.001]
  • [Cites] EMBO J. 1984 May;3(5):1151-7 [6329740.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3812-5 [6304740.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] World J Gastroenterol. 1998 Aug;4(4):298-302 [11819303.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):47-52 [10374676.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1967-73 [1326398.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] Int J Cancer. 1983 Nov 15;32(5):563-5 [6315601.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1247-61 [15648945.001]
  • [Cites] Science. 1989 Feb 17;243(4893):934-7 [2537532.001]
  • [Cites] Obstet Gynecol. 2004 Oct;104(4):751-5 [15458897.001]
  • (PMID = 16998682.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


39. Du Y, Li Z, Li L, Chen ZG, Sun SY, Chen P, Shin DM, Khuri FR, Fu H: Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. J Recept Signal Transduct Res; 2009;29(3-4):182-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
  • Targeting dysregulated signaling pathways in tumors has led to the development of a novel class of signal transduction inhibitors, including inhibitors of the epidermal growth factor (EGF) receptor (EGFR).
  • Here we report the application of a label-free optical biosensor to reveal the rapid response of cancer cells to EGF, expressed as a dynamic mass redistribution (DMR) signal.
  • In response to EGF, squamous cell carcinoma of the head and neck cells exhibited a rapid rise in DMR signal, whereas lung adenocarcinoma cells showed a biphasic DMR profile, suggesting a cell type-dependent DMR response.
  • The assay can also be used for cell-based high-throughput screening of EGF pathway inhibitors, as demonstrated by its robust performance in a 384-well plate format (Z' > 0.5).
  • [MeSH-minor] Antineoplastic Agents / isolation & purification. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Erlotinib Hydrochloride. Humans. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2005 Aug 1;579(19):4175-80 [16038906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002 [14967461.001]
  • [Cites] Med Res Rev. 2006 Sep;26(5):569-94 [16788977.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:666-9 [17282270.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):97-107 [18473353.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25 [16736979.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] J Biomol Screen. 1999;4(2):67-73 [10838414.001]
  • [Cites] Cancer Control. 2007 Jul;14(3):295-304 [17615536.001]
  • [Cites] Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim [16562649.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5720-5 [16131087.001]
  • [Cites] Assay Drug Dev Technol. 2006 Oct;4(5):583-95 [17115929.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):35-45 [17098420.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3540-5 [8758924.001]
  • [Cites] Biophys J. 2006 Sep 1;91(5):1925-40 [16766609.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:195-217 [14744244.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Biol Chem. 1988 Mar 5;263(7):3496-500 [2830286.001]
  • [Cites] Annu Rev Biochem. 1998;67:481-507 [9759495.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] Biotechnol J. 2008 Apr;3(4):484-95 [18412175.001]
  • [Cites] Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85 [17382029.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4249s-4253s [15217968.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):65-71 [18097577.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23 [19038731.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] ScientificWorldJournal. 2008;8:909-19 [18836658.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):824-32 [9625170.001]
  • (PMID = 19604037.001).
  • [ISSN] 1532-4281
  • [Journal-full-title] Journal of receptor and signal transduction research
  • [ISO-abbreviation] J. Recept. Signal Transduct. Res.
  • [Language] eng
  • [Grant] United States / NHGRI NIH HHS / HG / U54 HG003918; United States / NCI NIH HHS / CA / 5 P50 CA128613; United States / NCI NIH HHS / CA / P01 CA116676-04; United States / NHGRI NIH HHS / HG / 5U54 HG003918; United States / NHGRI NIH HHS / HG / U54 HG003918-03; United States / NCI NIH HHS / CA / P01 CA116676; United States / NCI NIH HHS / CA / T32 CA160040; United States / NCI NIH HHS / CA / P50 CA128613-03; United States / NCI NIH HHS / CA / P50 CA128613
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 62229-50-9 / Epidermal Growth Factor; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS142951; NLM/ PMC3746742
  •  go-up   go-down


40. Kreuter A, Brockmeyer NH, Pfister H, Altmeyer P, Wieland U, Competence Network HIV/AIDS: Human papillomavirus type 26-associated periungual squamous cell carcinoma in situ in a HIV-infected patient with concomitant penile and anal intraepithelial neoplasia. J Am Acad Dermatol; 2005 Oct;53(4):737-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type 26-associated periungual squamous cell carcinoma in situ in a HIV-infected patient with concomitant penile and anal intraepithelial neoplasia.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / virology. HIV Infections / epidemiology. HIV-1. Nail Diseases / epidemiology. Papillomaviridae. Papillomavirus Infections / epidemiology. Penile Neoplasms / epidemiology. Skin Neoplasms / epidemiology


41. Engstrom PF, Arnoletti JP, Benson AB 3rd, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C, NCCN: NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw; 2010 Jan;8(1):106-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NCCN clinical practice guidelines in oncology. Anal carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064293.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


42. Fernández-Fernández FJ, Buño-Ramilo B, Alvarez-Fernández JC, Brage-Gómez MS, Nogueira C: [Paraneoplastic hypercalcemia associated with a rectal epidermoid tumor in a patient with a long-standing anal fistula]. Gastroenterol Hepatol; 2010 Aug-Sep;33(7):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic hypercalcemia associated with a rectal epidermoid tumor in a patient with a long-standing anal fistula].
  • [Transliterated title] Hipercalcemia paraneoplásica asociada a una tumoración epidermoide rectal en una paciente con fístula anal de larga duración.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Hypercalcemia / etiology. Paraneoplastic Syndromes / etiology. Rectal Fistula / complications. Rectal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20381202.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


43. Bacchiocchi R, Rubini C, Pierpaoli E, Borghetti G, Procacci P, Nocini PF, Santarelli A, Rocchetti R, Ciavarella D, Lo Muzio L, Fazioli F: Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer; 2008;8:220
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
  • BACKGROUND: Oral squamous cell carcinoma (OSCC) represents the most common oral malignancy.
  • Among tumour progression biomarkers, already known for their involvement in other neoplasia, a crucial role is ascribed to the urokinase-type plasminogen activator receptor (uPAR), which plays a multiple role in extracellular proteolysis, cell migration and tissue remodelling not only as a receptor for the zymogen pro-uPA but also as a component for cell adhesion and as a chemoattractant.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods. Mouth Neoplasms / diagnosis. Prognosis. Receptors, Cell Surface / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):498-504 [10897110.001]
  • [Cites] Br J Oral Maxillofac Surg. 2007 Dec;45(8):623-7 [17590247.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2524-33 [12467066.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Jun;32(3):233-45 [12767868.001]
  • [Cites] Anal Quant Cytol Histol. 2004 Feb;26(1):15-21 [15032076.001]
  • [Cites] FEBS Lett. 1991 Aug 19;288(1-2):233-6 [1715292.001]
  • [Cites] Eur J Cancer. 1991;27(11):1445-8 [1660294.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):73-80 [8386710.001]
  • [Cites] Lancet. 1994 Aug 6;344(8919):401-2 [7914317.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4671-5 [8062262.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1035-43 [8635120.001]
  • [Cites] Immunol Today. 1997 Sep;18(9):415-7 [9293155.001]
  • [Cites] In Vivo. 1998 Jan-Feb;12(1):135-42 [9575435.001]
  • [Cites] Oral Oncol. 1998 Jan;34(1):58-62 [9659521.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1079-87 [9815897.001]
  • [Cites] Laryngorhinootologie. 1999 Mar;78(3):131-8 [10226980.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2948-56 [16395714.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13021-9 [16510444.001]
  • [Cites] Br J Oral Maxillofac Surg. 2006 Dec;44(6):515-9 [16356605.001]
  • [Cites] Biochem J. 2007 Oct 15;407(2):153-9 [17880283.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23869-76 [10791952.001]
  • (PMID = 18673553.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator
  • [Other-IDs] NLM/ PMC2527016
  •  go-up   go-down


44. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


45. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP: Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics; 2009 Dec;8(12):2746-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.
  • Detection of lung cancer at an early stage is necessary for successful therapy and improved survival rates.
  • We performed a bottom-up proteomics analysis using a two-dimensional LC-MS/MS strategy on the conditioned media of four lung cancer cell lines of different histological backgrounds (non-small cell lung cancer: H23 (adenocarcinoma), H520 (squamous cell carcinoma), and H460 (large cell carcinoma); small cell lung cancer: H1688) to identify secreted or membrane-bound proteins that could be useful as novel lung cancer biomarkers.
  • We also identified known or putative lung cancer tumor markers such as squamous cell carcinoma antigen, carcinoembryonic antigen, chromogranin A, creatine kinase BB, progastrin-releasing peptide, neural cell adhesion molecule, and tumor M2-PK.
  • To select the most promising candidates for validation, we performed tissue specificity assays, functional classifications, literature searches for association to cancer, and a comparison of our proteome with the proteome of lung-related diseases and serum.
  • Five novel lung cancer candidates, ADAM-17, osteoprotegerin, pentraxin 3, follistatin, and tumor necrosis factor receptor superfamily member 1A were preliminarily validated in the serum of patients with lung cancer and healthy controls.
  • Our results demonstrate the utility of this cell culture proteomics approach to identify secreted and shed proteins that are potentially useful as serological markers for lung cancer.
  • [MeSH-minor] ADAM Proteins / metabolism. Animals. CHO Cells. Cell Line, Tumor. Chromatography, Liquid. Cricetinae. Cricetulus. Extracellular Space / metabolism. Humans. Mass Spectrometry. Membrane Proteins / metabolism. Neoplasm Proteins / chemistry. Neoplasm Proteins / classification. Neoplasm Proteins / metabolism. Proteome / chemistry. Proteome / metabolism. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2006 Dec;6(23):6354-69 [17133372.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7009-17 [17145822.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2405-22 [17110383.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1083-92 [17284061.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4615-23 [17973440.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2793-8 [17941001.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):660-7 [18245525.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1355-62 [18316555.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2326-33 [18413821.001]
  • [Cites] Ann Oncol. 2008 Jun;19(6):1075-81 [18238782.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3329-38 [18578523.001]
  • [Cites] Biol Chem. 2008 Jun;389(6):781-6 [18627302.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):8325-31 [17227756.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2335-43 [17438092.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1039-49 [17277044.001]
  • [Cites] Cancer Sci. 2007 Aug;98(8):1265-74 [17537172.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2859-65 [17567164.001]
  • [Cites] Endocrinology. 1999 Nov;140(11):5303-9 [10537161.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5053-8 [11326667.001]
  • [Cites] Lung Cancer. 2001 May;32(2):137-44 [11325484.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2B):1241-6 [11396194.001]
  • [Cites] Electrophoresis. 2001 Oct;22(17):3629-38 [11699900.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2306-10 [12114435.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Eur Respir J. 2003 Mar;21(3):414-20 [12661994.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):905 [14586448.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):347-55 [14729644.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):399-409 [14726492.001]
  • [Cites] Biomarkers. 2004 Jan-Feb;9(1):56-70 [15204311.001]
  • [Cites] Proteomics. 2004 Jul;4(7):1985-8 [15221759.001]
  • [Cites] Clin Chem. 2007 Aug;53(8):1423-32 [17573418.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1406-15 [17495049.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1997-2011 [17656355.001]
  • [Cites] Lung. 2008 Sep-Oct;186(5):323-6 [18663529.001]
  • [Cites] J Proteome Res. 2006 Oct;5(10):2743-53 [17022645.001]
  • [Cites] Clin Biochem. 2004 Sep;37(9):823-9 [15329323.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1794-802 [15386310.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):927-33 [15386364.001]
  • [Cites] Neoplasma. 1991;38(2):129-35 [1645850.001]
  • [Cites] Neoplasma. 1991;38(6):645-51 [1766488.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):312-6 [1313391.001]
  • [Cites] J Biol Chem. 1992 Nov 5;267(31):22190-7 [1429570.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):418-25 [8391379.001]
  • [Cites] Int J Cancer Suppl. 1994;8:49-52 [7515029.001]
  • [Cites] Endocrinology. 1996 Feb;137(2):486-94 [8593793.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1227-32 [8630283.001]
  • [Cites] Exp Cell Res. 1996 Sep 15;227(2):230-9 [8831561.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3851-8 [9360551.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1714-28 [15800970.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1073-85 [16083256.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1274-86 [16083277.001]
  • [Cites] Proteomics. 2005 Jul;5(11):2949-59 [15996010.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3475-90 [16047398.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1251-64 [15951573.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1480-6 [15970581.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1826-30 [16103422.001]
  • [Cites] Respir Res. 2005;6:118 [16236163.001]
  • [Cites] Tumour Biol. 2006;27(1):8-16 [16340245.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):39-50 [16843264.001]
  • [Cites] Proteomics. 2006 Aug;6(15):4390-401 [16819730.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):87-94 [16876904.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):95-102 [16890323.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1727-44 [16887931.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1921-6 [16896060.001]
  • (PMID = 19776420.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Culture Media, Conditioned; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Proteome; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  • [Other-IDs] NLM/ PMC2816016
  •  go-up   go-down


46. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P, Swoboda J, Pfister H, Wieland U, German Competence Network HIV/AIDS: Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol; 2008 Aug;128(8):2078-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men.
  • Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal carcinoma, is highly prevalent in HIV-infected men having sex with men (MSM).
  • Standardized follow-up examinations included high-resolution anoscopy, anal cytology/histology, HPV typing, and DNA load determination for HPV types 16, 18, 31, and 33.
  • During follow-up, 58% of all patients (11/19) developed new anal cytological abnormalities in previously normal, untreated anal regions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma in Situ / drug therapy. DNA, Viral / drug effects. HIV Infections / complications. Papillomaviridae / genetics

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273049.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / DNA, Viral; 99011-02-6 / imiquimod
  • [Investigator] Adam A; Schewe K; Weitner L; Aratesh K; Arendt G; Bartz C; Behrens G; Beichert M; Bieniek B; Cordes C; Bochow M; Brockmeyer N; Buchholz B; Bogner JR; Buhk T; Clad A; Dannecker M; Dupke S; von Einsiedel R; Esser S; Faetkenheuer G; Fischer K; Freiwald M; Friebe-Hoffmann U; Fenske S; Funk M; Ganschow R; Gingelmaier A; Glaunsinger T; Goebel FD; Gölz J; Grosch-Wörner I; Haberl A; Hamouda O; Harrer T; Hartmann M; Hartl H; Hölscher M; Hower M; Husstedt IW; Jansen K; Jäger H; Jessen H; Jessen A; Karwat M; Klausen G; Kirchhoff F; Knechten H; Köppe S; Kreuter A; Kuhlmann B; Langer P; Lauenroth-Mai; Lehmacher W; Lehmann M; Levin C; Lübke M; Maschke M; Marcus U; Mauss S; Meyerhans A; Meyer-Olson D; ter Meulen V; Michalik C; Moll A; Mosthaf FA; Mutz A; Neuen-Jacob E; Niehues T; Oette M; Paulus U; Plettenberg A; Potthoff A; Racz P; Racz K; Rasokat H; Rausch M; Reichelt D; Reitter A; Rieke A; Rockstroh J; Salzberger B; Schafberger A; Schauer J; Schlote F; Schmidt B; Schranz D; Scholten S; Schuler C; Schwab M; Schmidt W; Schmidt R; Schwarze S; Siffert W; Skaletz-Rorowski A; Sonnenberg-Schwan U; Sopper S; Spengler U; Staszewski S; Steffan E; Stellbrink HJ; Stoll M; Goecke T; Taubert S; Telschik A; Ulmer A; Ullrich R; Uberla K; Usadel S; Vogel M; Wagner R; Walter H; Warnatz K; Wasem J; Wiesel W; Von Weizsäcker K; Wieland U; Wintergerst U; Wolf E; Wolf H; Wünsche T; Wyen Ch; Zeitz M; Zylka-Menhorn V
  •  go-up   go-down


47. Allal AS, Bründler MA, Gervaz P: Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus. Int J Colorectal Dis; 2005 Mar;20(2):161-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus.
  • BACKGROUND: Histologically, tumors of the anal region are either keratinizing (K) or non-keratinizing (NK) squamous cell carcinomas (SCCA).
  • METHODS: We performed an immunohistochemical analysis on 98 pre-treatment biopsies of patients with anal canal cancers.
  • The more distal the tumor is (anal margin), the more frequently the keratinizing subtype is observed (87 vs. 23%, p=0.0002).
  • [MeSH-major] Anus Neoplasms / metabolism. Apoptosis. Carcinoma, Squamous Cell / metabolism. Keratinocytes / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Pathology. 2002 Dec;34(6):573-8 [12555997.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):210-4 [9683295.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 Aug;97(2):223-30 [11451553.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):214-9 [12562647.001]
  • [Cites] J Clin Pathol. 1997 Aug;50(8):625-34 [9301544.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):345-52 [10888420.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):33-6 [9059353.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):753-7 [9973228.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):805-15 [9264365.001]
  • (PMID = 15688099.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


48. Vieira FL, Vieira BJ, Guimaraes MA, Aarestrup FM: Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading. BMC Oral Health; 2008;8:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading.
  • BACKGROUND: Squamous cells carcinoma is the most important malignant tumor with primary site in the oral cavity and, given the great exposure of mucosa and lips to the etiologic factors of this neoplasm, its incidence is high.
  • METHODS: In this study, oral mucosa samples of squamous cells carcinoma were analyzed, separated according to their histological classification as well as the phenotypical profile of the cells comprising the peritumoral inflammatory infiltrate was investigated by immunohistochemical method, in addiction, the cell proliferation index via protein Ki67 expression was determinated.
  • The B lymhocytes were the second most visualized leucocyte cell type followed by macrophages and neutrophils.
  • The immunohistochemical assessment of Ki-67 positive cells revealed a greater expression of this protein in samples of undifferentiated squamous cells carcinoma.
  • CONCLUSION: The results suggest that the cellular immune response is the main defense mechanism in squamous cells carcinoma of oral mucosa, expressed by the large number of T lymphocytes and macrophages, and that the greatest intensity of local response may be associated with the best prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAAPA. 2007 Oct;20(10):42-7 [18019328.001]
  • [Cites] Oral Oncol. 2001 Feb;37(2):164-71 [11167144.001]
  • [Cites] Acta Otorrinolaringol Esp. 2007 Oct;58(8):341-6 [17949660.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Aug;36(8):671-9 [17643963.001]
  • [Cites] Minerva Stomatol. 2007 Jun;56(6):341-7 [17625491.001]
  • [Cites] Pancreatology. 2006;6(5):450-3 [16847382.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):329-34 [16820911.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):717-27 [16520032.001]
  • [Cites] Braz J Otorhinolaryngol. 2005 Mar-Apr;71(2):181-7 [16446915.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jan;130(1):57-61 [16390239.001]
  • [Cites] Br J Oral Maxillofac Surg. 2005 Dec;43(6):511-2 [15908082.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jul;54(7):671-6 [15625605.001]
  • [Cites] Harefuah. 2005 Apr;144(4):243-5, 304, 303 [15889605.001]
  • [Cites] Br J Oral Maxillofac Surg. 2005 Jun;43(3):253-5 [15888363.001]
  • [Cites] J Periodontol. 2005 Mar;76(3):406-10 [15857075.001]
  • [Cites] Laryngoscope. 2005 Apr;115(4):690-8 [15805883.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jan;99(1):64-70 [15599350.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1382-97 [10364156.001]
  • [Cites] Arch Pathol Lab Med. 1998 May;122(5):447-54 [9593347.001]
  • [Cites] Aust Dent J. 1996 Apr;41(2):91-6 [8670041.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]
  • [Cites] Anal Cell Pathol. 1989 Feb;1(1):25-39 [2488698.001]
  • [Cites] Acta Pathol Jpn. 1993 Mar;43(3):99-106 [8484337.001]
  • [Cites] Br J Oral Surg. 1983 Jun;21(2):136-46 [6575816.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1319-29 [15319236.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2004 Apr;22(2):109-11 [15190789.001]
  • [Cites] Shanghai Kou Qiang Yi Xue. 2002 Dec;11(4):350-2 [14983378.001]
  • [Cites] Oral Oncol. 2003 Jul;39(5):459-69 [12747970.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38159-67 [12138162.001]
  • [Cites] Exp Cell Res. 2001 Nov 1;270(2):259-67 [11640889.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3661-6 [17972532.001]
  • (PMID = 18764952.001).
  • [ISSN] 1472-6831
  • [Journal-full-title] BMC oral health
  • [ISO-abbreviation] BMC Oral Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556313
  •  go-up   go-down


49. Siekas LL, Aboulafia DM: Establishing an anal dysplasia clinic for HIV-infected men: initial experience. AIDS Read; 2009 May;19(5):178-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing an anal dysplasia clinic for HIV-infected men: initial experience.
  • Anal dysplasia caused by human papillomavirus (HPV) infection is common in the HIV-infected population and is a precursor to squamous cell carcinoma of the anus (SCCA).
  • Herein, we describe our initial experience in assessing the frequency and severity of anal intraepithelial neoplasia (AIN) in a newly formed anal dysplasia clinic in Seattle.
  • We anticipate that the anal dysplasia clinic will enable our institution to participate in emerging HIV- and HPV-related AIN clinical trials.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma in Situ / etiology. Carcinoma, Squamous Cell / etiology. HIV Infections / epidemiology. Precancerous Conditions / etiology


50. Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villiers EM: E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol; 2006 Nov;80(22):11153-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice.
  • Histological and immunohistochemical examination of skin samples revealed enhanced proliferation of the epidermal layers and papilloma formation in both transgenic strains in comparison to what was observed with nontransgenic mice.
  • Squamous cell carcinoma developed in the HPV-20 E6/E7 transgenic line as well as in the HPV-27 E6/E7 transgenic line.
  • Several weeks after cessation of UV-B exposure, enhanced proliferation, as measured by BrdU incorporation, was maintained only in HPV-20 transgenic skin.
  • Keratin 6 expression was increased in the transgenic mice throughout all cell layers.
  • Expression of the differentiation markers involucrin and loricrin was reduced and disturbed. p63alpha expression was differentially regulated with high levels of cytoplasmic expression in clusters of cells in the granular layer of the skin in the transgenic lines 20 weeks after cessation of UV-B exposure, in contrast to uninterrupted staining in the nontransgenic lines. p53 was expressed in clusters of cells in nontransgenic and HPV-27 transgenic mice, in contrast to an even distribution in a higher number of cells in HPV-20 transgenic animals.
  • [MeSH-major] Alphapapillomavirus / metabolism. Betapapillomavirus / metabolism. Cell Differentiation. Cell Proliferation. Oncogene Proteins, Viral / biosynthesis. Skin / radiation effects. Skin / virology
  • [MeSH-minor] Animals. Bromodeoxyuridine / metabolism. Epidermis / metabolism. Epidermis / radiation effects. Epidermis / virology. Female. Histocytochemistry. Immunohistochemistry. Keratin-6 / biosynthesis. Male. Membrane Proteins / biosynthesis. Mice. Mice, Transgenic. Papilloma / pathology. Papilloma / virology. Papillomavirus Infections / virology. Phosphoproteins / biosynthesis. Protein Precursors / biosynthesis. Skin Neoplasms / pathology. Skin Neoplasms / virology. Trans-Activators / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Feb 10;19(6):821-6 [10698500.001]
  • [Cites] Mol Carcinog. 2005 Jan;42(1):40-52 [15547921.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1975-81 [11106570.001]
  • [Cites] Genes Dev. 2000 Dec 1;14(23):3065-73 [11114894.001]
  • [Cites] J Invest Dermatol. 2001 Feb;116(2):330-8 [11180011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61 [11248048.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):384 [11255361.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):828-34 [11275987.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1247-53 [11583952.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):1857-70 [12058054.001]
  • [Cites] Virology. 2002 Jul 5;298(2):240-7 [12127787.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):42268-79 [12200429.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):64-73 [12890196.001]
  • [Cites] J Virol. 2003 Oct;77(19):10186-201 [12970404.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Genes Dev. 2004 Jan 15;18(2):126-31 [14729569.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):949-57 [15149508.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):13-22 [15191537.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):411-3 [14976425.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1771-8 [15105299.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Cell Biol. 1989 Jul;109(1):295-307 [2473080.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2490-5 [15699322.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1394-400 [15735026.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):91-106 [15748641.001]
  • [Cites] Cell Cycle. 2005 May;4(5):689-96 [15846070.001]
  • [Cites] J Virol. 2005 Dec;79(23):14899-908 [16282489.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):201-7 [10623668.001]
  • [Cites] Cell. 1990 Aug 24;62(4):697-708 [1696852.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] J Virol. 1991 Jun;65(6):3335-9 [1851881.001]
  • [Cites] Arch Virol. 1992;125(1-4):355-60 [1642560.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4216-20 [8483937.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5583-7 [8390671.001]
  • [Cites] Curr Top Microbiol Immunol. 1994;186:157-75 [8205840.001]
  • [Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]
  • [Cites] Cell Growth Differ. 1994 Jun;5(6):667-75 [7522035.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8250-8 [7969162.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Arch Dermatol. 1995 Nov;131(11):1312-8 [7503577.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):274-8 [8552621.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 19;88(12):802-11 [8637046.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):2021-30 [8999895.001]
  • [Cites] Arch Dermatol Res. 1996 Dec;289(1):28-34 [9017132.001]
  • [Cites] Carcinogenesis. 1997 May;18(5):897-904 [9163673.001]
  • [Cites] J Invest Dermatol. 1997 Sep;109(3):340-7 [9284102.001]
  • [Cites] Clin Exp Dermatol. 1997 Jan;22(1):11-6 [9330045.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):356-61 [9359482.001]
  • [Cites] Virology. 1997 Dec 8;239(1):132-49 [9426453.001]
  • [Cites] Virology. 1997 Dec 22;239(2):296-302 [9434721.001]
  • [Cites] J Virol. 1998 Jun;72(6):5016-24 [9573271.001]
  • [Cites] Mol Carcinog. 1998 Jul;22(3):167-74 [9688142.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4591-602 [10493513.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):413-22 [10712888.001]
  • (PMID = 16971438.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-6; 0 / Membrane Proteins; 0 / Oncogene Proteins, Viral; 0 / Phosphoproteins; 0 / Protein Precursors; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 0 / Tumor Suppressor Protein p53; 0 / loricrin; 60108-77-2 / involucrin; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC1642157
  •  go-up   go-down


51. Satoh S, Nakashima T, Watanabe K, Toda S, Kuratomi Y, Sugihara H, Inokuchi A: Hypopharyngeal squamous cell carcinoma bordering ectopic gastric mucosa "inlet patch" of the cervical esophagus. Auris Nasus Larynx; 2007 Mar;34(1):135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopharyngeal squamous cell carcinoma bordering ectopic gastric mucosa "inlet patch" of the cervical esophagus.
  • We report here a case of hypopharyngeal squamous cell carcinoma bordering on IP of the cervical esophagus.
  • METHODS: A 44-year-old female underwent partial pharyngectomy, total laryngectomy, cervical esophagectomy, and bilateral neck dissection under the diagnosis of hypopharyngeal carcinoma.
  • RESULTS: Resected specimens of the hypopharynx revealed a well-differentiated squamous cell carcinoma in the ulcerative tumorous lesion (3.5 cm x 0.5 cm).
  • A brown patch (2 cm x 1.5 cm) bordering the anal aspect of the tumor comprised ectopic gastric mucosa of fundic type epithelium.
  • CONCLUSION: The hypopharyngeal squamous cell carcinoma likely developed in association with chronic irritation due to gastric acid from the IP.
  • To our knowledge, this is the first reported case of squamous cell carcinoma related to IP.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Choristoma / pathology. Esophageal Diseases / pathology. Gastric Mucosa. Hypopharyngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949237.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


52. Shi X, Yuan X, Tao D, Gong J, Hu G: Analysis of DNA ploidy, cell cycle and Ki67 antigen in nasopharyngeal carcinoma by flow cytometry. J Huazhong Univ Sci Technolog Med Sci; 2005;25(2):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of DNA ploidy, cell cycle and Ki67 antigen in nasopharyngeal carcinoma by flow cytometry.
  • The expression of DNA ploidy, the cell cycle and Ki67 antigen in nasopharyngeal carcinoma (NPC) were studied and their relationship with the clinical biological behaviors and prognosis of NPC was evaluated.
  • Biopsied specimens of NPC were made into cell suspension.
  • By using cytometric double labeling Ki67 and DNA method, the expression of DNA ploidy, the cell cycle and Ki67 antigen were analyzed.
  • The S phase cells accounted for 0 to 54% in the cell cycle and the positive expression of Ki67 ranged from 0 to 52%.
  • The patients having a low expression of Ki67 or DNA aneuploid in tumor cells were not sensitive to chemotherapy, liable to metastasis to distant organs and had a poor prognosis, while Ki67 showed no correlation with DNA ploidy and the cell cycle.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. DNA, Neoplasm / genetics. Ki-67 Antigen / immunology. Nasopharyngeal Neoplasms / immunology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ai Zheng. 2002 Jun;21(6):644-50 [12452067.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Aug;21(4):311-8 [10560508.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1030-8 [9060543.001]
  • [Cites] Int J Radiat Biol. 1999 Feb;75(2):143-53 [10072175.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Sep;20(3):371-6 [11718217.001]
  • [Cites] J Pathol. 1997 May;182(1):62-7 [9227343.001]
  • [Cites] Semin Oncol. 1994 Jun;21(3):330-9 [8209264.001]
  • [Cites] Surgery. 1991 Nov;110(5):814-9 [1948649.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):597-603 [9681528.001]
  • [Cites] Cytometry. 1994 Nov 1;17(3):258-65 [7851161.001]
  • (PMID = 16116972.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Ki-67 Antigen
  •  go-up   go-down


53. Haboubi N: Anal cancer; do we all have a common treatment strategy? Colorectal Dis; 2009 Nov;11(9):891-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer; do we all have a common treatment strategy?
  • [MeSH-major] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832862.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  •  go-up   go-down


54. Nadal SR, Manzione CR, Horta SH: Comparison of perianal diseases in HIV-positive patients during periods before and after protease inhibitors use: what changed in the 21st century. Dis Colon Rectum; 2008 Oct;51(10):1491-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of perianal diseases in HIV-positive patients during periods before and after protease inhibitors use: what changed in the 21st century.
  • Thus, the immunologic status of such patients has been improving and we believe that changes in their perianal diseases also have been occurring.
  • RESULTS: In Group 1, the most common diseases were condylomas (24.7 percent), ulcers (21.8 percent), and anal fistulas (19.7 percent).
  • Tumors occurred in 2.5 percent, with Kaposi's sarcoma in 51.1 percent, and squamous-cell carcinoma in 27.6 percent.
  • The tumor incidence was 1.8 percent, with squamous-cell carcinoma in 59.4 percent and Kaposi's sarcoma in 23.2 percent.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670819.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protease Inhibitors
  •  go-up   go-down


55. Nilsson PJ, Lenander C, Rubio C, Auer G, Ljungqvist O, Glimelius B: Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep; 2006 Sep;16(3):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of Cyclin A in epidermoid anal cancer.
  • Ultimately aiming at a more individualized therapeutic approach in epidermoid anal cancer, this study explored the prognostic and predictive impact of a set of tumour markers.
  • From a population-based cohort of 276 patients with epidermoid anal cancer, treated according to prospective protocols, 215 pre-treatment biopsies were investigated using immunohistochemistry.
  • Cyclin A may be an indicator of radiosensitivity and a valuable prognostic marker in epidermoid anal cancer.
  • [MeSH-major] Anus Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Cyclin A / metabolism

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865241.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


56. Devaraj B, Cosman BC: Expectant management of anal squamous dysplasia in patients with HIV. Dis Colon Rectum; 2006 Jan;49(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expectant management of anal squamous dysplasia in patients with HIV.
  • PURPOSE: Anal squamous dysplasia is commonly found in patients with HIV infection.
  • This study reviews a series of patients with HIV and an abnormal anal examination who had squamous dysplasia and who have been followed with physical examination alone and with repeat biopsies as necessary for new or suspicious lesions.
  • METHODS: We reviewed the charts of 40 HIV-positive men who had squamous dysplasia of the anal canal and anal margin, focusing on history, physical findings, histologic diagnosis, and the occurrence of invasive squamous-cell carcinoma.
  • RESULTS: Forty HIV-positive men (mean age, 39 years) were followed for anal squamous dysplasia.
  • Three patients developed invasive carcinoma while under surveillance, and these were completely excised or cured with chemoradiation.
  • In a group of patients followed expectantly, most did not develop invasive cancer, and in those who did, early cancers could be identified and cured.
  • Physical examination surveillance for invasive carcinoma may be acceptable for following patients with HIV and biopsy-proven squamous dysplasia.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Colectomy / methods. Decision Making. HIV / immunology. HIV Antibodies / immunology. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2006 Oct;49(10):1648-9; author reply 1649-50 [16972138.001]
  • (PMID = 16283561.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Antibodies
  •  go-up   go-down


57. Ge MJ, Wu QC, Wang M, Zhang YH, Li LB: Detection of disseminated lung cancer cells in regional lymph nodes by assay of CK19 reverse transcriptase polymerase chain reaction and its clinical significance. J Cancer Res Clin Oncol; 2005 Oct;131(10):662-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of disseminated lung cancer cells in regional lymph nodes by assay of CK19 reverse transcriptase polymerase chain reaction and its clinical significance.
  • RT-PCR) that can be used to detect disseminated tumor cells (DTCs) in regional lymph nodes (LNs) in patients with lung cancer and to evaluate its clinical significance.
  • Serial dilution study for LC-5 cells (a lung squamous cell line) was performed to detect sensitivity of the molecular protocol.
  • Regional LNs (n = 261) and primary lung cancer tissue (n = 40) were obtained from 40 patients with lung cancer who underwent lobectomy or pneumonectomy.
  • They were randomly categorized into two groups: group I (LN-based study, n = 20) and group II (patient-based study, n = 20).
  • Each LN was halved.
  • One half of a LN was subjected to histological examination (HE) and the other half was subjected to RT-PCR amplification of CK(19) mRNA.
  • RESULTS: CK(19) mRNA expressed in all tumor tissues as well as LC-5, PAa cells (a lung adenocarcinoma cell line), but not in normal control LNs.
  • Serial dilution study for LC-5 cells demonstrated that CK(19) mRNA was detectable at a concentration as low as 10 LC-5 cells in 1x10(7) LN cells.
  • There was no significant difference between the detecting result of single LN and that of mixed LNs (P > 0.05).
  • According to the results of regional LNs in 40 patients by molecular assay, the presence of the CK(19) product in LNs was related to tumor size (chi(2) = 5.76, P < 0.025) as well as cell differentiation of the tumor (chi(2) = 7.08, P < 0.01).
  • Molecular detection of DTCs in LNs is a supplement for current tumor staging in lung carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Keratins / biosynthesis. Lung Neoplasms / diagnosis. Lymphatic Metastasis / diagnosis. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Aged. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Messenger / analysis. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 1998 Jun 10;15(3):170-2 [9621128.001]
  • [Cites] Chest. 1998 Jun;113(6):1526-32 [9631789.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1350-7 [11350905.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Nov;122(5):900-6 [11689794.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2001 Sep;49(9):545-51 [11577444.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6472-8 [11103815.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1128-36 [11181678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(18):6133-7 [2994062.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Ann Thorac Surg. 1998 Nov;66(5):1715-8 [9875777.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):375-81 [11144532.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2326-32 [10873083.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Sep;20(3):481-8 [11509267.001]
  • [Cites] Cancer Lett. 2000 Nov 10;160(1):115-23 [11098092.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1369-81 [8787692.001]
  • [Cites] Ann Thorac Surg. 2002 May;73(5):1558-62 [12022549.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):306-12 [15661557.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4041-8 [11751499.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491 [11882819.001]
  • [Cites] Eur J Cell Biol. 1988 Dec;47(2):300-19 [2468493.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2002 Jan;24(1):41-3 [11977636.001]
  • [Cites] Ann Thorac Surg. 2001 Jun;71(6):1772-7; discussion 1777-8 [11426746.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1639-42 [8932347.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):1111-8 [7682761.001]
  • [Cites] JSLS. 1998 Oct-Dec;2(4):331-6 [10036123.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1437-43 [11230489.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):133-9 [11753052.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2640-4 [7540108.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4176-85 [11106229.001]
  • (PMID = 16047189.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 68238-35-7 / Keratins
  •  go-up   go-down


58. Herat A, Whitfeld M, Hillman R: Anal intraepithelial neoplasia and anal cancer in dermatological practice. Australas J Dermatol; 2007 Aug;48(3):143-53; quiz 154-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia and anal cancer in dermatological practice.
  • Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer.
  • Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer.
  • Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions.
  • Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population.
  • The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer.
  • However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
  • It is currently not proven that they reduce the likelihood of the development of anal cancer.
  • Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
  • In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomavirus Infections
  • [MeSH-minor] Diagnosis, Differential. HIV Infections / complications. Humans. Papillomaviridae / pathogenicity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680964.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 115
  •  go-up   go-down


59. Ciobotaru B, Leiman G, St John T, Hyman N, Ramundo M, Grace C: Prevalence and risk factors for anal cytologic abnormalities and human papillomavirus infection in a rural population of HIV-infected males. Dis Colon Rectum; 2007 Jul;50(7):1011-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and risk factors for anal cytologic abnormalities and human papillomavirus infection in a rural population of HIV-infected males.
  • PURPOSE: This study was designed to determine the prevalence and risk factors for anal squamous intraepithelial lesions and human papillomavirus infection in a rural population of HIV-infected males.
  • Anal Papanicolaou smear and human papillomavirus screening for oncogenic types were performed.
  • Ninety (60 percent) males had abnormal anal cytology, including atypical cells of unknown significance 40 (26 percent), low-grade squamous intraepithelial lesions 28 (19 percent), and high-grade squamous intraepithelial lesions 22 (15 percent).
  • Binary logistic regression adjusted risks for abnormal anal cytology included: males who have sex with males (P<0.001), human papillomavirus infection (P<0.001), history of anogenital warts (P=0.014), and the mean lowest CD4 count (abnormal cytology, 158 (standard deviation, 135), negative cytology, 208 (standard deviation, 180; P=0.017)).
  • Twenty-two patients with high-grade squamous intraepithelial lesions underwent colorectal surgical examination and anoscopy.
  • Two (10 percent) were found to have invasive squamous-cell carcinoma and three (15 percent) others had mass lesions with high-grade squamous intraepithelial lesions.
  • CONCLUSIONS: Anal squamous intraepithelial lesions and oncogenic human papillomavirus are highly prevalent in males infected with HIV and living in a rural setting.


60. Ortiz CM, Ito T, Hashimoto Y, Nagayama S, Iwai A, Tsunoda S, Sato F, Martorell M, Garcia JA, Perez A, Shimada Y: Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines. Diagn Pathol; 2010;5:41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines.
  • BACKGROUND: Fascin induces membrane protrusions and cell motility.
  • Fascin overexpression was associated with poor prognosis, and its downregulation reduces cell motility and invasiveness in esophageal squamous cell carcinoma (ESCC).
  • Using a stable knockdown cell line, we revealed the effect of fascin on cell growth, cell adhesion and tumor formation.
  • We established a stable transfectant with downregulated fascin from KYSE170 cell line.
  • RESULTS: The fascin downregulated cell lines showed a slower growth pattern by 40.3% (p < 0.01) and detachment from collagen-coated plates by 53.6% (p < 0.01), compared to mock cells, suggesting that fascin plays a role in cell growth by maintaining cell adhesion to the extracellular matrix.
  • CONCLUSIONS: These findings suggest that fascin overexpression plays a role in tumor growth and progression in ESCC and that cell death caused by its downregulation might be induced by cell adhesion loss.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carrier Proteins / genetics. Esophageal Neoplasms / genetics. Microfilament Proteins / genetics. RNA Interference. RNA, Small Interfering / metabolism
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / pharmacology. Animals. Apoptosis. Caspase Inhibitors. Caspases / metabolism. Cell Adhesion. Cell Line, Tumor. Cell Proliferation. Collagen / metabolism. Cysteine Proteinase Inhibitors / pharmacology. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Time Factors. Transfection. Tumor Burden. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] Thyroid. 2009 Jul;19(7):735-42 [19485776.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):421-5 [15157151.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Feb;86(4):1254-8 [2919174.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9115-9 [8415664.001]
  • [Cites] Biotechniques. 1993 Sep;15(3):532-4, 536-7 [7692896.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):249-56 [10806474.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4864-75 [11039904.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):338-45 [11123310.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G75-87 [11123200.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Cell Motil Cytoskeleton. 2001 Feb;48(2):109-20 [11169763.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1239-49 [11943709.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):987-91 [11956233.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):243-9 [12538476.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):1-7 [12689665.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]
  • [Cites] Curr Opin Cell Biol. 1994 Feb;6(1):105-9 [8167015.001]
  • [Cites] Semin Cell Biol. 1994 Jun;5(3):165-74 [7919230.001]
  • [Cites] J Virol. 1994 Nov;68(11):7320-8 [7933116.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2752-5 [7796399.001]
  • [Cites] Ann Surg Oncol. 1996 Jan;3(1):100-5 [8770310.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] Br J Dermatol. 1999 Aug;141(2):218-23 [10468791.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1154-64 [15712207.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5487-94 [16707478.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5267-75 [17122112.001]
  • [Cites] J Biomed Sci. 2009;16:100 [19917110.001]
  • [Cites] Cell Signal. 2007 Apr;19(4):761-71 [17113264.001]
  • [Cites] Apoptosis. 2007 Dec;12(12):2221-31 [17879163.001]
  • [Cites] Oncogene. 2007 Nov 8;26(51):7194-203 [17525740.001]
  • [Cites] Hum Pathol. 2009 Feb;40(2):174-80 [18835624.001]
  • [Cites] J Cell Biol. 2003 Nov 24;163(4):847-57 [14623871.001]
  • (PMID = 20565981.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Carrier Proteins; 0 / Caspase Inhibitors; 0 / Cysteine Proteinase Inhibitors; 0 / Microfilament Proteins; 0 / RNA, Small Interfering; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 146808-54-0 / fascin; 9007-34-5 / Collagen; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2907320
  •  go-up   go-down


61. Sotlar K: [Human papillomavirus infection. Pathology and molecular pathology]. Pathologe; 2008 Nov;29 Suppl 2:153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cervical cancer is the second most frequent female malignoma worldwide and accounts for about 500,000 cases every year.
  • Persistent infections with a group of 15 so-called high-risk human papillomaviruses (HR-HPV) are the cause of cervical carcinogenesis of squamous cell carcinomas and for most of the adenocarcinomas.
  • The resulting loss of cell cycle control sets the basis for additional, as yet only incompletely discovered, genetic and epigenetic changes, finally leading to invasive growth.
  • In addition to cervical cancer, HPV infections are responsible for the development of genital warts (condyloma) and a number of vaginal, vulvar, and anal intraepithelial neoplasias.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Child. Female. Humans. Middle Aged. Papillomaviridae / genetics. Papillomavirus Vaccines / administration & dosage. Young Adult


62. Esquibies AE, Zambrano E, Ziai J, Kesebir D, Touloukian RJ, Egan ME, Reyes-Múgica M, Bazzy-Asaad A: Pulmonary squamous cell carcinoma associated with repaired congenital tracheoesophageal fistula and esophageal atresia. Pediatr Pulmonol; 2010 Feb;45(2):202-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary squamous cell carcinoma associated with repaired congenital tracheoesophageal fistula and esophageal atresia.
  • We report a 19-year-old man with pulmonary squamous cell carcinoma (SCC) who had a history of vertebral, anal, cardiac, tracheal, esophageal, renal, and radial limb defects (VACTERL) association and tracheoesophageal fistula (TEF) + esophageal atresia (EA) repair as an infant.
  • Children that undergo TEF + EA repair may have an increased risk for developing cancer as they reach adulthood.
  • [MeSH-major] Abnormalities, Multiple / surgery. Carcinoma, Squamous Cell / etiology. Esophageal Atresia / surgery. Lung Neoplasms / etiology. Postoperative Complications / etiology. Tracheoesophageal Fistula / surgery


63. Jethwa P, Lake SP: Using topical negative pressure therapy to resolve wound failure following perineal resection. J Wound Care; 2005 Apr;14(4):166-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elective resection of the rectum and perineum in a patient with recurrent squamous cell carcinoma of the anus resulted in significant wound failure.
  • Full healing was achieved with topical negative pressure, with no recurrence of the cancer.
  • [MeSH-minor] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Humans. Male. Middle Aged. Recurrence. Suction / methods. Treatment Failure

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835227.001).
  • [ISSN] 0969-0700
  • [Journal-full-title] Journal of wound care
  • [ISO-abbreviation] J Wound Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Bakotic WL, Willis D, Birdsong G, Tadros TS: Anal cytology in an HIV-positive population: a retrospective analysis. Acta Cytol; 2005 Mar-Apr;49(2):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cytology in an HIV-positive population: a retrospective analysis.
  • OBJECTIVE: To retrospectively evaluate cellularity and correlate the presence of columnar cells with specimen interpretation in conventionally prepared anal cytologic smears from an HIV-positive population.
  • STUDY DESIGN: Two cytopathologists and 1 senior cytotechnologist, blinded to the original diagnosis, screened 114 samples from 110 patients collected between 1997 and 2002.
  • The relationships between diagnosis and presence of columnar cells, visible anal lesions, concurrent HIV viral load and CD4+ T-cell counts were assessed.
  • RESULTS: The cytologic findings were as follows: 7, unsatisfactory (6%); 29, negative (25%); 25, atypical squamous cells of undetermined significance (22%); and 53, dysplasia (47%) (42 anal intraepithelial lesion 1 [37%] and 11 anal intraepithelial lesion 2/3 [10%]).
  • CONCLUSION: A highly significant association between the presence of columnar cells and anal intraepithelial lesion (p<0.001) and a significant association between the presence of columnar cells and atypical cytology when a visible lesion was absent (p=0.0019) were found.
  • No significant relationship was found between the presence/degree of dysplasia and CD4+ T-cell counts or HIV viral load.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma / pathology. Epithelial Cells / pathology. HIV Infections / complications. HIV Seropositivity / complications
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Cell Biology / standards. Female. HIV / immunology. Humans. Immunocompromised Host. Male. Mass Screening. Middle Aged. Predictive Value of Tests. Retrospective Studies. Unsafe Sex. Viral Load


65. Goldstone SE, Kawalek AZ, Huyett JW: Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum; 2005 May;48(5):1042-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions.
  • PURPOSE: The incidence of invasive anal squamous carcinoma in men who have sex with men is rising, particularly in those with human immunodeficiency virus.
  • As in the cervix the high-grade squamous intraepithelial lesion is thought to be an invasive squamous cell carcinoma precursor.
  • Cervical high-grade squamous intraepithelial lesions are treated by removing the squamocolumnar transition zone.
  • This is not possible in the anus, where treatment is often surgical and is accompanied by significant pain and morbidity.
  • Better office-based techniques to treat anal high-grade squamous intraepithelial lesions are needed.
  • We employed the infrared coagulator in an office setting to ablate high-grade squamous intraepithelial lesions.
  • Procedures were performed with local anesthesia on patients with discrete high-grade squamous intraepithelial lesions.
  • Follow-up consisted of anal cytology with high-resolution anoscopy and biopsy of suspicious areas every three to six months.
  • However, 44 patients (65 percent) developed a new or persistent high-grade squamous intraepithelial lesion within a median time of 217 days (range 27-566 days) after infrared coagulation.
  • No patient developed squamous-cell carcinoma, had a serious adverse event, or developed anal stenosis.
  • CONCLUSIONS: The infrared coagulator is a safe, office-based modality for treating anal high-grade squamous intraepithelial lesion in human immunodeficiency virus-positive men who have sex with men.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. HIV Seropositivity. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery


66. Goldstone SE, Kawalek AZ, Goldstone RN, Goldstone AB: Hybrid Capture II detection of oncogenic human papillomavirus: a useful tool when evaluating men who have sex with men with atypical squamous cells of undetermined significance on anal cytology. Dis Colon Rectum; 2008 Jul;51(7):1130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid Capture II detection of oncogenic human papillomavirus: a useful tool when evaluating men who have sex with men with atypical squamous cells of undetermined significance on anal cytology.
  • PURPOSE: In the cervix and anus, patients with atypical squamous cells of undetermined significance often do not have high-grade squamous intraepithelial lesions.
  • In women with atypical squamous cells of undetermined significance, Hybrid-Capture II testing for oncogenic high-risk human papillomavirus is performed and those without high-risk human papillomavirus often are observed.
  • We endeavored to determine whether Hybrid-Capture II testing would be beneficial in men who have sex with men with atypical squamous cells of undetermined significance.
  • METHODS: We performed a retrospective chart review of men who have sex with men with atypical squamous cells of undetermined significance who had high-resolution anoscopy and Hybrid-Capture II.
  • High-grade squamous intraepithelial lesions were found in 50 (17 percent): 23 (10 percent) who were HIV-negative and 27 (35 percent) who were HIV-positive men.
  • Five percent with high-grade squamous intraepithelial lesions would be missed.
  • [MeSH-major] Alphapapillomavirus / genetics. Anal Canal / pathology. Carcinoma, Squamous Cell / pathology. Homosexuality, Male. Papillomavirus Infections / pathology. RNA, Viral / analysis. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Colonoscopy. Diagnosis, Differential. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Precancerous Conditions. Predictive Value of Tests. Prevalence. Retrospective Studies. Risk Factors. Sensitivity and Specificity. United States / epidemiology

  • MedlinePlus Health Information. consumer health - HPV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18481150.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


67. Damin DC, Rosito MA, Schwartsmann G: Sentinel lymph node in carcinoma of the anal canal: a review. Eur J Surg Oncol; 2006 Apr;32(3):247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node in carcinoma of the anal canal: a review.
  • AIMS: To review the studies investigating the efficacy of the sentinel lymph node (SLN) procedure in anal canal carcinoma and to evaluate its potential role in guiding a more selective approach for patients with the malignancy.
  • METHODS: A literature search in the PubMed database was preformed using the key words "sentinel lymph node" and "anal cancer".
  • All indexed original articles (except case reports) on the SLN procedure in cancer of the anal canal were analysed.
  • The detection of occult metastases in clinically unsuspicious nodes represents an important improvement in the process of staging these patients, which has not been possible with any other method of diagnosis.
  • Although SLN procedure is still in an early phase of investigation in this type of cancer, it emerges as an objective method to guide individual therapeutic decisions.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / secondary

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289647.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


68. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park); 2010 Apr 15;24(4):364-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
  • Although anal cancer is a rare disease, its incidence is increasing in men and women worldwide.
  • Anal cancer is generally preceded by high-grade anal intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus (HIV)-positive men who have sex with men.
  • Meta-analysis suggests that 80% of anal cancers could be avoided by vaccination against HPV 16/18.
  • Nearly half of all patients with anal cancer present with rectal bleeding.
  • Pain or sensation of a rectal mass is experienced in 30% of patients, whereas 20% have no tumor-specific symptoms.
  • According to the Surveillance Epidemiology and End Results (SEER) database, 50% of patients with anal cancer have disease localized to the anus, 29% have regional lymph node involvement or direct spread beyond the primary, and 12% have metastatic disease, while 9% have an unknown stage.
  • Clinical staging of anal carcinoma requires a digital rectal exam and a computed tomography scan of the chest, abdomen, and pelvis.
  • The 5-year relative survival rates are 80.1% for localized anal cancer, 60.7% for regional disease, and 29.4% for metastatic disease.
  • Part 2 of this two-part review will address the treatment of anal cancer, highlighting studies of chemoradiation.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Mass Screening

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464850.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


69. Kim JW, Abramson DH: Topical treatment options for conjunctival neoplasms. Clin Ophthalmol; 2008 Sep;2(3):503-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the past ten years, topical agents have been used by investigators to treat various premalignant and malignant lesions of the conjunctiva, such as primary acquired melanosis with atypia, conjunctival melanoma, squamous intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and pagetoid spread of the conjunctiva arising from sebaceous cell carcinoma.
  • In this review, we present specific guidelines for treating both melanocytic and squamous neoplasms of the conjunctiva, utilizing the available data in the literature as well as our own clinical experience at the Memorial Sloan-Kettering Cancer Center.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1997 Jul;81(7):595-8 [9290377.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1263-9 [9097762.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1338-44 [9097771.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Jpn J Ophthalmol. 2002 Mar-Apr;46(2):215-7 [12062230.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):248-55 [12040282.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):548-52 [11874760.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Int Ophthalmol Clin. 1993 Summer;33(3):25-30 [8407189.001]
  • [Cites] Acta Ophthalmol (Copenh). 1992 Jun;70(3):289-96 [1636385.001]
  • [Cites] JAMA. 1991 Sep 11;266(10):1375-83 [1715409.001]
  • [Cites] Trans Am Ophthalmol Soc. 1991;89:285-98; discussion 298-301 [1808811.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):317-21 [2023752.001]
  • [Cites] Surv Ophthalmol. 1989 May-Jun;33(6):477-90 [2658172.001]
  • [Cites] Br J Ophthalmol. 2002 Jan;86(1):31-4 [11801499.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Ophthalmology. 1994 Apr;101(4):759-62 [8152772.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Br J Ophthalmol. 1994 Jul;78(7):520-8 [7522545.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Br J Ophthalmol. 1994 Apr;78(4):252-9 [8199108.001]
  • [Cites] Arch Ophthalmol. 1994 Jan;112(1):22-3 [8285885.001]
  • [Cites] Ophthalmology. 1989 Feb;96(2):147-66 [2649838.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Doc Ophthalmol. 1986 Dec 30;64(1):31-42 [3582100.001]
  • [Cites] Am J Ophthalmol. 1986 Jul 15;102(1):87-90 [3728630.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3 [3980172.001]
  • [Cites] Ophthalmology. 1984 Jun;91(6):673-8 [6462625.001]
  • [Cites] Ophthalmic Surg. 1984 Apr;15(4):289-94 [6728400.001]
  • [Cites] Arch Ophthalmol. 1983 May;101(5):782-6 [6847469.001]
  • [Cites] J Urol. 1981 Oct;126(4):461-4 [6793738.001]
  • [Cites] Arch Ophthalmol. 1980 Aug;98(8):1385-9 [7417073.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Am J Ophthalmol. 1979 Jan;87(1):84-6 [434057.001]
  • [Cites] Doc Ophthalmol. 1973 Feb 21;34(1):93-108 [4706112.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1755-61 [15350333.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 May;88(5):718-9 [15090432.001]
  • [Cites] Br J Ophthalmol. 2004 Jan;88(1):17-8 [14693762.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1012-6 [12750105.001]
  • [Cites] Cornea. 2003 Mar;22(2):114-7 [12605043.001]
  • [Cites] Acta Ophthalmol Scand. 2002 Dec;80(6):674-5 [12485296.001]
  • [Cites] Am J Ophthalmol. 2001 Oct;132(4):576-8 [11589886.001]
  • [Cites] Br J Ophthalmol. 2001 Sep;85(9):1115-9 [11520767.001]
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2190-5 [11097594.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Oct;21(5):387-96 [10560521.001]
  • [Cites] Br J Ophthalmol. 2006 Jul;90(7):819-22 [16672325.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1108-14 [15940485.001]
  • [Cites] Cornea. 2005 May;24(4):443-8 [15829803.001]
  • [Cites] Cornea. 2005 Apr;24(3):297-300 [15778602.001]
  • [Cites] Am J Ophthalmol. 2005 Feb;139(2):229-34 [15733981.001]
  • [Cites] Arch Ophthalmol. 2005 Jan;123(1):109-13 [15642823.001]
  • [Cites] Am J Ophthalmol. 1963 Apr;55:811-5 [13948673.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1756-60; discussion 1761 [10485547.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • (PMID = 19668748.001).
  • [ISSN] 1177-5467
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2694026
  • [Keywords] NOTNLM ; 5-Fluorouracil / Mitomycin-C / conjunctival neoplasms melanosis / topical therapies
  •  go-up   go-down


70. Pineda CE, Berry JM, Welton ML: High resolution anoscopy and targeted treatment of high-grade squamous intraepithelial lesions. Dis Colon Rectum; 2006 Jan;49(1):126
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution anoscopy and targeted treatment of high-grade squamous intraepithelial lesions.
  • PURPOSE: The purpose of this video is to illustrate the use of high resolution anoscopy in the diagnosis and treatment of anal high-grade squamous intraepithelial lesions.
  • METHODS: Five patients with anal dysplasia were examined in the operating room with acetic acid and the operative microscope.
  • Acetic acid is generously applied to aide in the recognition of high-grade squamous intraepithelial lesions.
  • Acetowhite regions are examined under the operative microscope to further distinguish lesions as either low-grade squamous intraepithelial lesions or high-grade squamous intraepithelial lesions.
  • These lesions are selectively destroyed under direct visualization with an effort to maintain normal mucosa and skin to prevent stenosis.
  • Some pigmented lesions contain high-grade squamous intraepithelial lesions; the operative microscope is used in this setting to look for the vascular characteristics of high-grade disease.
  • RESULTS: The video reports five male patients treated for high-grade squamous intraepithelial lesions with the aide of high resolution anoscopy.
  • All lesions suspicious for high-grade squamous intraepithelial lesions based on observed vascular patterns were confirmed as such with permanent histopathology.
  • CONCLUSION: The use of acetic acid and the operative microscope with selective use of Lugol's solution accentuates the visual characteristics of high-grade lesions, enhancing the surgeon's ability to target treatment to high-grade squamous intraepithelial lesions.
  • High resolution anoscopy is useful in the targeted treatment of high-grade squamous intraepithelial lesions.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Colonoscopy / methods. Image Enhancement. Video-Assisted Surgery / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222485.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Theelen W, Speel EJ, Herfs M, Reijans M, Simons G, Meulemans EV, Baldewijns MM, Ramaekers FC, Somja J, Delvenne P, Hopman AH: Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-assay. Am J Pathol; 2010 Oct;177(4):2022-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncogenic human papillomavirus (HPV) infection is the most important risk factor in cervical carcinogenesis cases; high viral loads, viral integration into the host genome, and gain of the telomerase-related genes, TERT and TERC, are all factors associated with progression to cancer.
  • Only 5 out of 37 normal tissue samples or low-grade cervical lesions (ie, CIN1 and condyloma) showed either an HPV16 viral load higher than 25 copies per cell, viral integration, and/or gain of one of the telomerase-related genes, whereas for the high-grade cervical lesions, one or more of these risk factors was found in 25 of 30 cases.
  • Furthermore, the feasibility of the MLPA assay was shown for cytological samples, where in 57% of high-grade squamous intraepithelial lesion cases, the high-risk factors were detected using this assay.
  • [MeSH-major] Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / diagnosis. Telomerase / genetics. Uterine Cervical Neoplasms / diagnosis. Viral Load. Virus Integration
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / etiology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / etiology. DNA, Viral / genetics. Feasibility Studies. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Nucleic Acid Amplification Techniques. Polymerase Chain Reaction. Uterus / metabolism. Uterus / pathology. Young Adult


72. Ito B, Niwa Y, Ando N, Ohmiya N, Miyahara R, Ohashi A, Itoh A, Hirooka Y, Goto H: Diagnosis of the depth of invasion of esophageal carcinoma using digital radiography. Eur J Radiol; 2005 Jun;54(3):377-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of the depth of invasion of esophageal carcinoma using digital radiography.
  • OBJECTIVE: The purpose of our investigation was to determine the usefulness of digital radiography (DR) for diagnosing the depth of invasion of esophageal carcinoma.
  • Percent esophageal stenosis (PES) was based on the diameter across the lesion of maximal narrowing and the average of the normal oral and anal side diameters.
  • [MeSH-major] Carcinoma, Squamous Cell / radiography. Esophageal Neoplasms / radiography. Radiographic Image Enhancement

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899339.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


73. Nair KS, Naidoo R, Chetty R: Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol; 2005 Apr;58(4):343-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value.
  • Oesophageal carcinoma remains a disease of poor prognosis.
  • It has been established that the initial step in the metastatic cascade is the detachment of tumour cells from the primary tumour via dysregulation of normal cell-cell and cell-matrix interactions.
  • Distinct proteins known as cell adhesion molecules (CAMs) mediate these interactions.
  • This review provides a brief description of five families of CAMs (cadherins, integrins, CD44, immunoglobulin superfamily, and selectins) and highlights their altered expression in relation both to prognosis and tumour behaviour in squamous cell carcinoma and adenocarcinoma of the oesophagus.
  • [MeSH-major] Cell Adhesion Molecules / analysis. Esophageal Neoplasms / chemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Antigens, CD44 / analysis. Cadherins / analysis. Carcinoma, Squamous Cell / chemistry. Humans. Integrins / analysis. Neoplasm Metastasis. Prognosis. Selectins / analysis